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DEFINITION OF TERMS 
People Living with HIV 
(PLWHIV). 
: This is defined as people living with HIV. 
Acquiring HIV no longer means certain death. 
It has been changed to a chronic illness 
under treatment medication.   
 
People living with AIDS. 
(PLWA). 
: This is defined as people living with an  
acquired immune deficiency syndrome 
(AIDS). These could be infants, children or 
adults. This is the recommended term due to 
the fact that it shows that individuals who are 
infected may continue to live longer and 
productively (UNAIDS, 2007). 
 
Test-retest Reliability. : This is defined as the quality of being 
trustworthy or of performing consistently well 
over an interval of time. 
 
Construct Validity  
(CV). 
: This is the degree to which an outcome tool 
measures what it claims, or purports, to be 
measuring. 
 
Lower Extremity Functional Scale  
(LEFS). 
: This is an outcome measure that is used to 
measure the lower limb functional activities 
and movements.   
Distal Sensory Peripheral Neuropathy ;   damage to or disease affecting nerves, which 
may impair sensation, movement, or other 
aspects of health, depending on the type of 
nerve affected. In this study we are looking to 
causes by the use of the antiretroviral 
medication. 
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ABSTRACT 
Background: The Human Immunodeficiency Virus (HIV) and the Acquired Immune 
Deficiency Syndrome (AIDS) have posed a serious disease burden on society. The side 
effects issuing from the anti`-retroviral drugs (ARVs) include Distal Sensory Peripheral 
Neuropathy (DSPN), a common neurological complication. The Lower Extremity Functional 
Scale (LLFS) is a reliable and valid tool that has been used for measuring the lower limb 
functional capacity of patients presenting with DSPN in countries other than Botswana.  As 
such, it is necessary to test its test-retest reliability in Botswana. 
Aim: The aim of this study was to determine the test-retest reliability of the Lower Extremity 
Functional Scale (LEFS) among HIV-related DSPN patients in Botswana.  
Methodology: This study involved a test-retest reliability study based on a time interval of 
seven to 10 days. A total of 320 HIV patients from six hospitals in Gaborone, Botswana, 
were screened for DSPN according to the relevant inclusion and exclusion criteria .The 
percentage of the total patients who were diagnosed with DSPN was 26.3% (84). The lower 
extremity functional scale LEFS questionnaire was administered twice with a seven to 10-
day period interval and the results of the assessment were recorded and analysed.  
Measurements of central tendencies were used to summarize the demographic data and the 
clinical information for the lower extremity functional scale information obtained. Because the 
data sets were categorical, Spearman’s correlation analysis was conducted to determine the 
efficacy of the test-retest reliability. 
Furthermore, the Intraclass correlation (ICC) was used for measuring the internal 
consistency of the LEFS questionnaire. Demographic data such as age, gender, education 
and marital status, and clinical information pertaining to the participants were used to 
describe them.  
Results: A total of 84 HIV patients from six hospitals who were on anti-retroviral therapy 
(ART) and presenting with DSPN participated in the study. The test-retest reliability was 
found to range from rs=0.74-0.99, ICC = 0.96. SEM=4.88 
xiv 
 
Conclusion: The study results showed strong test-retest reliability and good internal 
consistency. Hence, the LEFS questionnaire can be considered reliable as a standard   from 
which to monitor lower limb functionality in HIV-related Distal Sensory Peripheral Neuropathy 
among patients in Botswana.  
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CHAPTER ONE: INTRODUCTION 
1.1. BACKGROUND 
Both the Human Immunodeficiency Virus (HIV) and the Acquired Immune Deficiency 
Syndrome (AIDS) have been prevalent in the human population for over three 
decades. In the ensuing years, interest in the measurement of self-reported 
functioning and wellbeing, or health-related quality of life (HRQOL), in HIV-infected 
individuals has been extensive (Gabel et al., 2012). Although there is still no cure for 
HIV, the increased use of anti-retroviral therapy (ART) has led to substantial 
improvements in AIDS-free survival and also the decline in mortality in HIV-infected 
individuals (Murphy et al., 2001, Krentz et al., 2005, Cettomai et al., 2010). 
Modifications to the natural progress  of the HIV disease through the use of anti-
retroviral drugs  have in fact had diverse effects, both beneficial and toxic,  on 
patients since these drugs have significantly improved the  quality of life in the patient 
population but also have significant side effects (Brinley Jr et al., 2001).  
 
HIV, recognised as  a chronic disease, has been reported to have a long-term effect 
on the mental, sensory and perceptive functions and the genitourinary,  
cardiovascular and respiratory systems of human beings (Hanass-Hancock et al., 
2013). In fact, Distal Sensory Peripheral Neuropathy (DSPN) is the most common 
neurological complication issuing from the use of anti-retroviral drugs (ARVs) by HIV 
patients (Manji and Miller, 2004, Gonzalez-Duarte et al., 2007, Nicholas et al., 2010, 
Wadley et al., 2011).  
 
The prevalence of peripheral neuropathy among people living with HIV (PLHIV) 
patients receiving ARV treatment in South Africa has been reported to be as high as 
49% (Maritz et al., 2010). DSPN is widely undiagnosed and undertreated in most 
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medical institutions, and more especially in resource-limited settings (Cettomai et al., 
2010).  
 
The long-term use of ARVs has been associated with peripheral neuropathies (Ellis 
et al., 2008, Cettomai et al., 2010). The ARVs most commonly used in developing 
countries were Isoniazid and Stavudine (Robertson et al., 2008).  It has been  
reported in the literature that these drugs predispose patients who have been 
diagnosed with HIV  to symptoms of peripheral neuropathy (Cettomai et al., 2010). 
The specific pathophysiology of DSPN, although a common complication of the HIV 
disease, is not well understood.  However, there has been evidence to suggest that 
the long-term use of ARVs results in mitochondrial toxicity, which subsequently  
results in tissue damage (Gardner et al., 2014).  
 
In rehabilitation, there is a dearth of knowledge concerning the optimal interventions 
to improve lower extremity function and to manage such symptoms. In sub-Saharan 
Africa, only two studies from  Kenya and Rwanda have used the lower limb functional 
scale as an outcome measure to evaluate lower limb function in HIV patients 
diagnosed with DSPN (Cettomai et al., 2010, Tumusiime, 2014).  
 
The Lower Extremity Functional Scale (LEFS) is a reliable tool that has been used to 
detect the functioning of the lower limbs (Binkley et al., 1999). Hence, it enables the 
assessor to determine the functionality and the quality of life of the patient. The LEFS  
has been found to be both reliable and valid  in  evaluating lower limb function on 
account of  the musculoskeletal problems that are so prevalent in  the lower limbs of  
the elderly and the middle aged (Watson et al., 2005, Στασή et al., 2015).  
Hoogeboom et al. (2012) evaluated the reliability and validity of the LEFS in 
evaluating lower limb function in patients with osteoarthritis of the hip and knee. It 
has been shown that the LEFS tool, in conjunction with other outcome measures 
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associated with hip and knee arthritis, such as the Hip Osteoarthritis Outcome Score 
and the Knee Osteoarthritis Outcome Score, is reliable and valid. The study by 
Hoogeboom et al. (2012) showed that the LEFS obtained  higher specificity and 
sensitivity levels in the evaluation of lower limb impairment as opposed  to those 
obtained by the Western Ontario and McMaster Universities Osteoarthritis Physical 
Function  (WOMAC PF) Scale.  
 
The LEFS questionnaire has been reported to have good measurement properties, 
namely test-retest reliability and cross-sectional construct validity.  As such,  it could 
be an alternative to the WOMAC-PF Scale (Cettomai et al., 2010).  
 
An Italian version of the LEFS has been found to be reliable, valid and responsive in 
measuring lower limb impairment in people suffering from  musculoskeletal problems 
(Cacchio et al., 2010). In sub-Saharan Africa, in Kenya and Rwanda specifically,  the 
LEFS questionnaire has been used to effectively evaluate lower limb function and   
has been found to be reliable and valid (Cettomai et al., 2010, Tumusiime, 2014).  
 
Since individuals with HIV are surviving longer, often in fact living for decades with 
the disease, chronic comorbidity such as DSPN must be addressed (Keswani et al., 
2002). It is important, therefore, to include the management of peripheral neuropathy 
which is a common problem recognised among HIV patients when the holistic 
intervention approach is applied (Myezwa et al., 2009, Nicholas et al., 2010). 
Furthermore, the characterization of lower extremity function in HIV patients  and 
their quality of life (QOL) must also be addressed  in order to provide clinicians with 
optimal outcome assessments to measure DSPN changes with treatment over time 
(Ellis et al., 2008, Nicholas et al., 2010).  
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Evidence on the test-retest reliability of the LEFS in the evaluation of lower limb 
impairment among HIV patients is scanty.  Because only two studies in sub-Saharan 
Africa have used the LEFS as an outcome measure among HIV patients (Cettomai et 
al., 2010, Tumusiime, 2014). A similar study in Botswana, also in sub-Saharan Africa,  
would, according to the UNAIDS report in 2015 (UNAIDS, 2015) be welcomed in that 
Botswana has a high prevalence of HIV with an estimated 350 000 people living with 
HIV/AIDS. 
 
There is much evidence of long-term comorbidity of HIV in Botswana’s  HIV 
population (Ansari et al., 2002, Gupta et al., 2010). There is thus a need for the 
Lower Extremity Functional Scale (LEFS)  to be used in this country since  this 
outcomes measure is easy to administer and also to score (Binkley  et al., 1999). 
This study therefore set out to test the reliability of the LEFS questionnaire as an 
outcome measure in the identification of lower limb impairment among PLHIV 
patients in Botswana.  
 
1.2. RESEARCH PROBLEM 
The test-retest reliability of the Lower Extremity Functional Scale (LEFS) in the 
measurement of lower extremity function in HIV patients who are on ART (anti-
retroviral therapy) treatment was unknown in Botswana prior to the initiation of this 
study. 
 
1.3. AIM OF THE STUDY 
The aim of this study was therefore to determine the test–retest reliability of the LEFS 
as an outcome measurement tool to establish lower limb function in patients with HIV 
related DSPN in the case of Botswana. 
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1.4. OBJECTIVES OF THE STUDY 
 To establish the test-retest reliability of the LEFS in the measurement of lower 
limb function in HIV-related DSPN in Botswana 
 To determine the internal consistency of the LEFS for lower limb function in HIV-
related DSPN in Botswana 
 To describe the demographic and clinical characteristics of HIV patients with 
DSPN in Botswana  
 To determine the construct validity of the LEFS in participants with DSPN in 
Botswana. 
 
1.5. SIGNIFICANCE OF STUDY 
By establishing the test-retest reliability of the LEFS for patients with HIV related 
DSPN, through  identification tools which are both valid and reliable, rehabilitation 
professionals and other medical practitioners will  acquire  more information about 
DSPN patients’ problems The LEFS is recommended as a measure to determine the  
challenges that the patients in the sample are experiencing. The test-retest reliability 
of   the LEFS will provide better understanding of DSPN in Botswana.    
 
Peripheral neuropathy is one of the most common musculoskeletal problems among 
HIV patients and is associated with functional limitations. The extent of these 
limitations needs to be comprehensively assessed.  Therefore, this study sets out to 
provide information that will inform health professionals about rehabilitation outcome 
measures and provide a clearer picture of the lower limb functional outcomes of 
peripheral neuropathy in PLHIV patients in Botswana. 
 
1.6. GENERAL OUTLINE OF THE STUDY 
Chapter One 
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Chapter one is focused on the background to this study and the necessity for 
undertaking this research. A statement of the problem and the aims and objectives of 
this study are also presented in this chapter.  
Chapter Two 
Chapter Two focuses on a review of the relevant literature justifying the necessity for 
undertaking this project and the steps in the process of this study.  
Chapter Three 
Chapter Three focuses on the methodology of the study and includes the pilot study 
and the main study.  
Chapter Four 
This chapter is focused on presenting the results emanating from the statistical 
analysis of the data.  
Chapter Five 
Chapter Five focuses on a discussion and interpretation of the results of the study 
Chapter Six 
This is the final chapter in the thesis and it focuses on summarizing the study.  
 
1.7. SUMMARY OF CHAPTER ONE  
This chapter explains the background and the need for the test-retest reliability of the 
LEFS in HIV-related DSPN. The problem statement and the aims and objectives of 
the study are explained in this chapter.  
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2. CHAPTER TWO: LITERATURE REVIEW 
 
2.1. INTRODUCTION 
The literature review focuses on peripheral neuropathy as one of the most common 
side-effects of anti-retroviral therapy in people living with HIV. This chapter reviews 
the literature on the presentation and the limitations associated with peripheral 
neuropathy in people infected with HIV, with the main focus being on the test-retest 
reliability of the LEFS in HIV-related DSPN. 
 
The search engines used in this research included Google Scholar, the Google 
Search Website, Pubmed, and various physiotherapy journal publications, EBSCO, 
Cochrane Collaboration and Science Direct.  Key words used were Lower Limb 
Functional Scale (LEFS), Human-immunodeficiency Virus/Auto-immune Deficiency 
Syndrome (HIV/AIDS), validity, test-retest reliability, Distal Sensory Peripheral 
Neuropathy (DSPN), quality of life (QOL) and Anti-retroviral Therapy (ART). 
Physiotherapy articles pertaining to the Lower Extremity Functional Scale, and 
published between 1995 and 2016 were included in this review.  
 
2.2. EPIDEMIOLOGY OF THE PANDEMIC OF HIV/AIDS GLOBALLY 
There are approximately 36.7 million people in the world who are infected with HIV 
and the epicentre of the disease is in sub-Saharan Africa, especially in southern 
Africa (UNAIDS, 2011). As a result of  effective pharmacological management, as 
well as other policies and strategies, there has been  a significant reduction in the 
prevalence  of the pandemic in most southern African countries (Deanna Cettomai, 
2010). In the face of the high death rate of approximately two million people in the 
2010 decade, an  intensified  dispensation of highly aggressive  anti-retroviral 
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therapy was rolled out to  raise  the life expectancy among  people suffering from  
HIV and AIDS (Samji et al., 2013). 
 
Unfortunately, there are a number of related side effects of the anti-retroviral drugs.  
These are due to their neuro-toxic nature and the complications arising from the HIV 
infection.  Apart from, but also together with them, these  opportunistic infections  
have presented  a major medical challenge in the management of HIV (Nicholas et 
al., 2010). One of the complications of anti-retroviral drugs is Distal Sensory 
Peripheral Neuropathy. A summary of the impacts of HIV on the body systems is 
presented below.  
 
2.2.1. HIV Impacts on the Body Systems 
Systems affected by the HIV disease include the musculo-skeletal (Joseph and 
Habib, 2009), the nervous (Smurzynski et al., 2011), the respiratory (Ghezzi, 2011), 
the gastro-intestinal (Deeks et al., 2013) and  the immune systems (McMichael et al., 
2010).  
 
2.2.2. The Musculo-Skeletal System 
In the past, prior to the administration of ART,  gross muscle atrophy  or muscle 
mass loss tended to be the major clinical symptom signalling the occurrence of  HIV  
(Dubé et al., 2007). This was attributed to elevated levels of glucocorticoids and 
cytokines in the body which tended to slow down the process of protein synthesis 
and to increase the rate at which the muscle structure is broken down. The elevated 
glucocorticoids and cytokine, levels have their source largely in the recurrent and 
consecutive opportunistic infections that HIV-infected patients are vulnerable to. The 
afore-mentioned eventually lead to energy consumption in periods of resting and also 
to poor appetite, the final result being the emaciation of the individual. In fact, general 
9 
 
body wasting still remains a major impact that the HIV has on the body (Dubé et al., 
2007). 
 
2.2.3. The Central Nervous System 
Serious consequences for the nervous system also occur in HIV-infected patients.  
The final result when the human-immunodeficiency virus gains access to the brain is 
the destruction of the neurological cells of the central nervous system.  This is 
complicated by the fact  that there is reduced accessibility of the anti-retroviral drugs 
to penetrate the blood-brain barrier (Namanja et al., 2011).  
 
It was therefore not unexpected for a large proportion (two-thirds) of the participants 
in a study conducted in Gauteng to report that  they were presenting  with cognitive 
impairments (Hanass-Hancock et al., 2013). Dementia is one of the more commonly 
reported cognitive impairments  resulting from the HIV virus  (Hanass-Hancock et al., 
2015). 
 
The most common neurological complication experienced by patients with the HIV is 
DSPN (Tumusiime, 2014). It brings with it comorbidity too. Studies have shown that 
the prevalence of neuropathy in HIV patients ranges from 38% to 53% (Nicholas et 
al., 2010). Individuals with HIV–related DSPN experience pain, paraesthesia, 
numbness, and more especially the impairment of their lower limbs.  As a result, they 
suffer episodic disability (Phillips et al., 2010).  Their functionality is impaired, and  
they experience a decline in their  quality of life (Galantino et al., 2014). The use of 
ARVs aggravates the severity of peripheral neuropathy (Phillips et al., 2010). Some 
other risk factors compounding the problem of impaired lower limb function include 
advancing age and prior exposure to various kinds of anti-retroviral therapy 
regimens, as well as a longstanding history of HIV infection (Ances et al., 2012).  
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2.3. COMPLICATING FACTORS 
In the event of advanced HIV disease and the use of  substances and drugs other 
than the anti-retrovirals such as  alcohol,  marijuana or cocaine, the patient places 
himself at  great risk of contracting DSPN and could also suffer a  reduction in his/her 
CD4 count (Robinson‐Papp et al., 2012).  
 
Other adverse consequences in patients with HIV/AIDS on anti-retroviral therapy and 
resulting from unhealthy lifestyle practices in the form of substance and drug abuse 
do occasionally occur in conjunction with peripheral neuropathy. They include  
conditions such as lipodystrophy (Guaraldi et al., 2011)  which occurs in patients on 
the  Stavudine regimen. Their condition has been noted to be significantly different 
from those  on the Zidovudine antiretroviral regimen (Guaraldi et al., 2011). 
 
Other published literature sources point to  instances where distal sensory 
neuropathy presents in  patients that have not yet commenced  the antiretroviral 
therapy regimen (Robertson et al., 2008). Important to note is the fact that the 
occurrence of DSNP shows a  significant  association   with the destruction of the 
myelin sheath surrounding  the peripheral nerves which can generally be attributed to 
infection due to the human-immuno virus (Robertson et al., 2008).  
 
2.4. CLINICAL STAGES OF HIV/AIDS 
According to the World Health Organisation (WHO) classification, the progression of 
HIV is classified into four stages, as outlined in Table 2.1 below.  
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Table 2.1: WHO Clinical Stages of HIV/AIDS (World Health 
Organisation, 2007) 
HIV Stages Description of the Stages 
Stage 1 *  Asymptomatic persistent generalized lymphadenopathy  
 Moderate unexplained weight loss (<10% of the individual’s usual body 
weight) 
 Recurrent acute respiratory infections (ARIs), Occurrence of the Herpes 
Zoster Complex 
 
Stage 2 **  Angular cheilitis, recurrent oral ulceration, popular pruritic eruptions 
 Seborrheic dermatitis, fungal infections of the nails 
 More than 10% unexplained body weight loss as opposed to   the 
measured body weight 
 >one  month of unexplained chronic diarrhoea and intermittent or constant 
unexplained fever 
 Chronic oral thrush- candidiasis, oral hairy leucoplakia, current TB 
(tuberculosis). 
 
Stage 3 ***  Intense bacterial infections such as empyema, pneumonia, joint or bone 
infection, pyomyositis , bacteraemia and meningitis 
 Periodontitis, gingivitis or acute necrotizing ulcerative stomatitis 
 Insidious anaemia ( Hb <8g/dL), Neutropenia (neutrophils<500 cells/uL) 
 Thrombocytopenia which is chronic (platelets < 50,000 cells/uL) 
 HIV wasting syndrome, pneumocystic pneumonia 
 Bacterial pneumonia which is severe and recurrent 
  Herpes simplex infection which is chronic in areas; oesophageal 
candidiasis  
 Extra pulmonary TB, cancers such as Kaposi sarcoma 
 CMV cytomegalovirus infection (infections of other organs or renitis) 
 Central nervous system toxoplasmosis, encephalopathy due to HIV 
 Extra pulmonary cryptococcosis (inclusive of meningitis) 
 
Stage 4  Disseminated non TB mycobacterial infections 
 Progressive multifocal leukoencephalopathy 
 Lungs, bronchi and tracheal candida 
 Diarrhoea infection, chronic cryptosporidiosis 
 Disseminated mycosis (such as penicilliosis, histoplasmosis, 
coccidioidomycosis) 
 Chronic isosporiasis 
 Recurrent non-typhoidal Salmonella bacteria 
 Cerebral as well as B-cell non-Hodgkins lymphoma 
 Invasive cervical carcinoma 
 Disseminated leishmaniasis,  which is atypical 
 Symptomatic HIV–associated nephropathy and cardiomyopathy 
 Reactivation of the American trypanosomiasis (such as myocarditis or 
meningoencephalitis) 
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DSPN is commonly diagnosed in the third and fourth stages of the HIV disease (World 
Health Organisation, 2007).  
 
2.5. DISTAL SENSORY PERIPHERAL NEUROPATHY IN HIV PATIENTS 
HIV affects the nervous system directly and indirectly in that it affects the nerves, 
nervous tissue and exacerbates opportunistic infections .Table 2.2 outlines the 
aetiology and signs and symptoms of some of the common conditions presenting in 
HIV and AIDS patients.  Included are the pathologies, signs and symptoms that are 
associated with the corresponding disease. 
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Table 2.2:  Summary of Peripheral Neuropathies Associated with HIV 
Condition Pathology Signs and symptoms References 
Guillain–Barré 
syndrome 
(Polyradiculopathy) 
This is an acute inflammatory 
demyelination that occurs. Both 
intracellular, as well as hormonal, 
pathways occur. There will be the 
crossing of the ganglioside surface by 
the foreign antigens.  
 
 
 
 
There is numbness, 
paraesthesia, weakness, 
pain of the limbs and on 
some occasions there will 
be a combination of the 
symptoms. Mostly there is 
progressive bilateral 
weakness of both limbs 
and the weakness 
progresses over a period 
of 12 hours to a period of 
28 days before a plateau 
is reached. It ultimately 
leads to respiratory 
complications.  
Yuki and 
Hartung 
(2012),  
Quinn (1997) 
Sensory 
neuropathy and 
related or unrelated 
peripheral nerve 
dysfunction. 
Neurotoxins produced by the 
mycobacterium avium complex and 
cytomegalovirus.  They  are the cause 
of loss of distal sensory nerves 
(axonal degeneration) and the 
unmyelinated nerves (Gale, 2003). 
ARVs are also causative agents of 
sensory peripheral neuropathy 
through  the chemical destruction of 
the nerve myelin sheaths and this 
leads to disrupted nerve conduction 
(Manji and Miller, 2004). Injury occurs 
due to removal of the nerve myelin 
which facilitates the salutatory 
propagation of impulses and its 
insulation properties. Loss of the 
myelin results in nerve axonal 
degeneration and deterioration of 
nerve conduction (Gale, 2003).  
Worsened sensation is experienced 
when the  posterior root ganglia are 
affected (White et al., 2004)  
Changes in the perception 
of sensation, including 
pain, touch and 
temperature. Additionally 
patients experience 
hyperesthesia, 
paraesthesia and loss of 
proprioception.  
Gale (2003),  
Manji and 
Miller (2004), 
White et al. 
(2004)  
Progressive 
multifocal leuco-
encephalopathy. 
Infection of lymphocytes in the CNS 
may result in the multifocal cell lysis 
and demyelination. It can be due to 
the James Canyon virus (Brew et al., 
2010). 
Progressive hemiparesis 
Cognitive dysfunction 
Heminopia or ataxia 
Dysphagia and seizures  
Focal intracranial lesions 
(Manji and Miller, 2004). 
Manji and 
Miller (2004),  
Brew et al. 
(2010) 
Cytomelomegalo 
virus 
CMV cause focal necrosis with 
necrotising ventriculo-encephalitis 
imbroglio nodules. 
CMV renitis 
Rapid deliriumAltered 
mental status. 
Nystagmus 
Cranial neuropathies 
Kenneson 
and Cannon 
(2007) 
 
As outlined in Table 2.2 above, DSPN presents in several forms. Distal sensory 
peripheral neuropathy is one of the more common conditions that have emerged in 
the HIV disease trajectory. Clinical presentations of Distal Sensory Peripheral 
Neuropathy range from bilateral symmetrical polyneuropathy to monoradiculopathy 
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(seen on the unilateral side), to lumbar and brachial plexopathy, a syndrome that 
presents as diffuse infiltrative lymphocytosis (Sohal et al., 2009).  
 
Peripheral neuropathy can manifest as the Gullaine Barre syndrome (GBS) in the 
form of inflammatory demyelinating polyradiculoneuropathy (Sohal et al., 2009).  This 
type of neuropathy can be autonomic and  can present in different  forms at the  
different stages  in the trajectory of progressive polyradiculopathy (Kaku and 
Simpson, 2014).   
 
The occurrence of Distal Sensory Peripheral Neuropathy can be classified as  a 
largely sensory dysfunction when  there has primarily been injury to a sensory nerve 
(Hahn et al., 2008). DSPN is classified mainly as a sensory problem that manifests 
when the dorsal root ganglion is affected.  However, circumstances do arise when 
the anterior horn is affected, which results in motor dysfunction. Motor activity 
dysfunction may manifest as a weakness in and a twitching of the lower limb muscles 
(Hwang et al., 2009).  
 
A diagnosis of DSPN can be concluded by conducting a number of tests.  Testing the 
patella reflex, ankle and  the Achilles tendon reflex forms an important part of these 
diagnostic tests  (Hahn et al., 2008). Other diagnostic tests include the two-point 
discriminatory test for vibration and thermal sensation. These  reflex checks and 
sensory tests  confirm  the diagnosis of the  condition, DSPN, in HIV-infected  
patients and therefore explain   how the HIV and the related management strategies 
impact on  the nervous system (Phillips, 2013). The specific mechanism by which 
DSPN occurs has been described in the literature (Robinson‐Papp et al., 2012, 
Cherry et al., 2014).  
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2.5.1. Distal Sensory Peripheral Neuropathy Pathogenesis 
The pathogenesis of the disease process can occur when macrophages are infected 
by the virus. The virus destroys the posterior root nerve ganglia by producing 
antigens and inflammatory cytokines (Hahn et al., 2008). Macrophages exist as 
facilitators of the nervous system that help in controlling movement and in signalling 
the leukocytes into the nervous system and its tissue whenever there is  inflammation 
(Bhangoo et al., 2009). If the inflammatory process is lengthy or excessive, the  
clearing-up process to remove any infective pathogens eventually proves to be 
ineffective. The chances of infection and further pathology are then enhanced 
(Cherry et al., 2014).   
 
As described above, the HI virus acts independently and exerts a direct effect on the 
nervous system, eventually resulting in DSPN. Yet another mechanism that acts on 
the central nervous system has its source in  the HIV medication, which causes side 
effects to the body of the HIV patient and includes, amongst others,  DSPN (Cherry et 
al., 2014). 
 
2.5.2. Distal Sensory Neuropathy as a Side Effect of the HIV Drugs 
The main aim behind the administration of the anti-retroviral drugs and treatment is to 
control the viral load and raise the CD4+ count to facilitate the immune-boosting 
process. Some of the well-known anti-retroviral medication that causes peripheral 
neuropathy includes Didanosine (ddl), Zalcitabine (ddC) and Stavudine (d4T). These 
drugs fall into the category,  nucleoside reverse transcriptase inhibitors (NRTI) 
(National Drug and Therapeutics Policy Advisory Committee, 2010).  
 
These anti-retroviral regimens are divided into various categories including the 
following: protease inhibitors, non-nucleoside reverse transcriptors and nucleoside 
reverse transcriptase inhibitors. The nucleoside reverse transcriptase inhibitors inhibit 
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the HIV enzymes that facilitate the reverse transcriptase process, thus preventing the 
copying of the RNA to become the DNA of the infected cells through the formulation 
of deceptive deoxyribonucleic acid chains. This leads to an incomplete DNA strand 
which is not  able to assist in the development of  a mature virus (National Drug and 
Therapeutics Policy Advisory Committee, 2010). 
 
Most of the nucleoside reverse transcriptase inhibitors that are frequently used in 
Third World countries are permitted by the World Health Organisation (Bartlett and 
Gallant, 2000). Stavudine is one of the well-known nucleoside reverse transcriptase 
inhibiting drugs with familiar side-effects that are easily recognised. In contrast,  the 
protease inhibitors are of little risk to Distal Sensory Neuropathy (Evans et al., 2007).  
 
One of the more commonly known side-effects of anti-retroviral drugs is the  
increased occurrence of neuronal damage which makes potentially dormant 
peripheral neuropathy more evident (Keswani et al., 2002).  
 
2.5.2.1. Mitochondrial toxicity and peripheral neuropathy caused by HIV drugs 
On account of their toxic effects, nucleoside inhibitors, such as  Stavudine, 
interfere with the mitochondrial oxidation in neuronal metabolic 
activities(Amanambu, 2013). The toxic effects of the Nucleoside Reverse 
Transcriptase Inhibitors (NRTIs) occur when intracellular tri-phosphorylation of 
the Nucleoside Reverse Transcriptase Inhibitors forms nucleotides which 
subsequently lead to the incorporation of the nucleotides into growing 
Deoxyribonucleic Acid (DNA) chains. This occurs  through the viral enzyme 
reverse transcriptase process, which terminates the continued formation of DNA  
(Amanambu, 2013).  
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Tri-phosphorylation of the Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
in the cells  results in two types of pharmacokinetic dispositions, one being a 
biologically inactive drug in the cell plasma and the second  being the active 
NRTIs phosphate in cells (Stretcher et al., 1994). Most clinical symptoms of 
NRTI toxicities are exhibited as mitochondrial disease, and microscopic 
investigations show abnormal mitochondria and/or the depletion of mitochondrial 
DNA (mtDNA)  in the cells and tissues that would have been affected (Dykens 
and Will, 2007).  
 
NRTI triphosphates competitively inhibit  the mtDNA polymerase y in vitro (Lewis, 
2003), which will lead to a reduction in the mitochondrial respiratory chain proteins 
and thus facilitate anaerobic respiration, induce oxidative stress, and elevate 
mutations in the mtDNA, finally culminating  in mitochondrial and,  on occasion, 
tissue failure (Lewis, 2003). However, despite the fact that the NRTIs are able to  
alter the mitochondrial genes (Desai et al., 2008)  the possible  link between HIV 
drugs and the roxicities which they cause, including lactic acidosis, and peripheral 
neuropathy, is mitochondrial toxicity (Côté et al., 2002).  
 
2.6. IMPAIRMENTS CAUSED BY HIIV-RELATED DISTAL SENSORY PERIPHERAL 
NEUROPATHY 
 
Complications and impairments that present  as a result of the HIV disease condition 
include muscular weakness, fatigue, lethargy, impaired sensory function, 
paraesthesia, imbalances in terms of the limbs, impairment of the activities of daily 
living, muscle dysfunction and issues related to the quality of life (Nicholas., 2012).  
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According to the International Classification of Function (ICF), functional human 
dimensions are categorised into domains which facilitate complete intervention after 
a functional assessment. Impairments are problems that are found in the bodily 
functions and structures such as significant deviation from normal body functions. or 
loss of functional activities of daily living (World Health Organization, 2001). Severe 
bodily impairments occur in the movement-related functions of the body, and the 
mental and neuro-muscular dimensions of the body (Myezwa et al., 2009).   
 
Disability is currently defined as an umbrella term for impairments, limitations on 
activity, and restrictions on participation in activities. The term disability denotes the 
negative aspects of the  interaction that occurs between an individual’s health 
condition(s) and that person’s contextual factors that include the personal and 
environmental factors (World Health Organization, 2001). 
 
Sensory disruptions and impairments are some  of the more common problems 
facing  patients  suffering from HIV/AIDS and have an impact on their neuro-
musculoskeletal functions (White et al., 2004). Sensory axonal and neuronal damage 
leads to limitations on functionality and activities because of the ensuing clinical 
symptoms such as pain, numbness, paraesthesia and poor proprioception (Cettomai 
et al., 2013). Some patients  face challenges such as those  of not being able to 
discriminate between  contrasting properties (e.g. between hot and cold), whereas 
others could  be hypersensitivity on the skin to  garments or textiles  (Cettomai et al., 
2013). 
 
2.6.1. Neuropathic Pain in HIV-Related DSPN 
According to the study by Verma et al. (2005), the other notable problem with HIV-
related DSPN is pain of a neuropathic origin. Pain is common in patients with 
symptomatic HIV-related DSPN and there are a number of factors that contribute to 
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the intensity of the pain experienced and that  concomitantly magnify the burden to 
be carried by the victims of this disease (Verma et al., 2005).   
 
The pathophysiology of the disease can be explained in terms of  the fact that, 
despite its cause, injury to the peripheral nerves will lead to a chain of molecular, 
anatomical and physiological changes (Mendell and Sahenk, 2003). Injury to the 
peripheral nerve fibres will result in abnormal stimulation being experienced by the 
victim in the vicinity  of the place  on the body where the injury occurred 
(Zimmermann, 2001).  
 
Once there is neuro-inflammation of the nerves, the neuro-immune system is 
activated.  This  in turn cascades down to the production of  chemokines, cytokines 
and surface antigens, especially in the dorsal/posterior root ganglion (DRG) (DeLeo 
and Yezierski, 2001, Liu et al., 2007). The upward regulation of membrane channels 
in the posterior root ganglion  and the distal peripheral nerves surrounding the place  
of injury will lower the activation threshold and result in  persistent pain  This will 
facilitate the  stimulation of the sensory fibres of the injured nerve (DeLeo and 
Yezierski, 2001). Injury to the nerve will cause the sympathetic axonal sprout 
surrounding the cell bodies and lead to an intensified response to the stimulation 
(Verma et al., 2005).  
 
2.6.2. Peripheral Neuropathy Leading to Muscular Dysfunction 
Peripheral neuropathy can lead to muscular dysfunction. The muscular dysfunction 
could include muscular twitching and cramps, as in the tightening of the muscles, as 
well as in a weakness being experienced in the intrinsic musculature of the foot, all 
as a result of neuronal impairment (Nicholas., 2012). The result of lactic acid 
accumulation as a by-product of the metabolism of the body, especially as a result of 
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anti-retroviral  drugs, can also be regarded as  one of the effects that disturbs muscle 
function (Phillips and Walker, 2004). 
 
There are instances involving  limitations on  the activity levels of a patient, resulting  
in a concomitant  reduction in the patient’s participation in daily activities such as 
grooming, and community activities such as his/her attendance at weddings and 
funerals (Gabel et al., 2012). Limitations on daily activities will lead to compromises 
having to be made in terms of the attainment of health-related quality of life. Such 
limitations would represent a relevant outcome for the various functional activities 
that are important to patients when the efficacy of any management modality that has 
to be implemented is considered and evaluated.  The objective would be to  enhance 
the functionality of the patients in their daily living activities (Bril et al., 2011).  
 
Some of the major areas that are of paramount importance to patients in their daily 
living include mobility, occupational and domestic activities, self-care, as well as 
recreational activities. Without a doubt, people suffering from HIV/AIDS would 
experience at least some of these limitations.  
 
Factors associated with limitations on  participation in activities in the case of patients 
suffering from DSPN would include lethargy, pain, paraesthesia, impaired 
proprioception, and depression (White et al., 2004). These compounding factors tend 
to present clinically as an impaired gait, reduced mobility and an elevated propensity 
to falling.  
 
Such findings are  also supported by Myezwa et al. (2009) who highlight the fact that 
most of the  limitations on activity in HIV patients includes bathing, mobility, sleeping, 
as well as other common activities of daily living. The main areas that might restrict 
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participation include those associated with family life as a parent or spouse, of self-
actualisation, and of pleasure in conducting occupational activities (Johnson., 2001). 
 
2.7. MEDICAL TREATMENT OF DISTAL SENSORY PERIPHERAL NEUROPATHY 
DSPN is currently managed through the  self- care approach and through therapeutic 
interventions, in the form of both non-pharmaceutical and drug therapies (Gale, 
2003). Such approaches correspond to those presented in the clinical context and to 
the preferred treatment plans prescribed and made available by medical practitioners 
(Nicholas., 2012).  
 
Drug therapies include the administration of analgesics and other anti-retroviral 
medication to alleviate the clinical symptoms of DSPN. There are some drugs such 
as anti-convulsants that are used to reduce pain.  They include gabapentin, 
carbazapine and pregabalin, as well as sodium valproate (Bril et al., 2011).  
 
As a complement to drug therapies, there are alternative therapies such as 
physiotherapy modalities which are also applied to alleviate pain in the case of DSPN  
(Gale, 2003) The physiotherapy modalities that are used include therapeutic 
exercises (i.e. aerobic exercises, progressive resistance exercises) and generalised 
home exercise programmes such as walking (Nicholas et al., 2007).  
 
Other modalities include acupuncture, massage and electrotherapy (e.g.TENS and 
IFT) (Verma and Simpson, 2007). Electrotherapy has been used as a non-drug 
therapy for neuropathies and includes interferential therapy, procedures such as 
transcutaneous electrical nerve stimulation and functional electrical nerve stimulation 
(Pieber et al., 2010).  
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In addition to electrotherapy, massage is effective in relieving pain. Massage and its 
variations, ranging from kneading, effleurage, petrissage, rhythmic stroking and rapid 
stroking, could all be collectively termed as Swedish massage (Ashton and Cassel, 
2006). The effect that massaging has is to inhibit the pain pathways from stretch or 
pain receptors and to improve the quality of life.  Massaging  could be used in 
conjunction with the other modalities such as  relaxation, acupuncture and the other 
oriental treatments   (Galantino et al., 2006). Oriental practices such as Tai Chi, in  
combination with aerobic exercises, improve endurance, flexibility and balance in 
candidates suffering  from DSPN (Nicholas et al., 2007).  
 
Some of the strategies that have been shown to work as self-care strategies include 
hot and cold contrasting baths, pedal massage, humour, the  elevation of the feet, 
rest, exercise, the use of herbs (including cannabis), prayer, a change of diet,  
environmental change, ambulation for long periods and some therapeutic exercises 
(Ownby and Dune, 2007).   
 
Any practical physical activity that  mitigates  the symptoms of an illness,  a disease 
or a condition, or improves the condition of the patient, thus promoting his/her 
physical health and slowing down the deterioration of his/her condition, is known as  
therapeutic exercise.  However,  most of the medical personnel are reluctant to 
prescribe exercise for patients for fear of exhaustion,  which is believed to  tend 
towards the  suppression of the immune system and fatigue (Taylor et al., 2007). The  
numerous programmes to  improve  muscle strength, as well as endurance, include 
cycling, jogging,  running, and a fast as well as a normal  walking  pace (White et al., 
2004). 
 
Prescribed exercises can be defined as prescribed physical activities as laid out in a 
protocol for an individual to conduct voluntarily in order to improve his/her good 
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health status or delay  the deterioration thereof (Taylor et al., 2007). Therapeutic 
exercises performed at a sub-maximal level are used to predict maximal heart rate 
levels.  Combined with resistance exercises, they  have a significantly  beneficial 
effect on the cardio-vascular and immune systems, on viral control and on fitness 
levels (O'Brien et al., 2008).  
 
The various body-strengthening modalities include static exercises, supervised 
aerobic exercises and resistance exercises. They have a significant effect on the 
recovery  of HIV patients and the rate at which the recovery  takes place, and also 
improve the muscle strength of the individual (White et al., 2004). 
  
2.8. OUTCOME MEASURES 
‘Outcome measures’ is the term for the results of a test or an investigation that is 
used in an objective manner to monitor or determine the initial baseline level of 
function of a participant at the commencement of an investigation or treatment. Once 
the investigation or treatment has started, the same tool or measure can be used to 
determine any change that has occurred since the beginning of the investigation 
(Benbow et al., 1998).   
 
2.9. PSYCHOMETRIC PROPERTIES OF OUTCOME MEASURES 
“Psychometric properties” refers to the statistical properties of an instrument that is 
used to collect data for study purposes. This includes validity and reliability.  
Reliability refers to the consistency of the tool when used on two or more occasions, 
whilst validity refers to the accuracy of the tool when used on each occasion. The 
reliability of an instrument helps the researcher to make  a valid assessment and it is 
the  validity of the instrument that enables the researcher to be confident in making 
statistical predictions (Tesch, 2013).  
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2.9.1. Validity  
Validity implies that the outcome measures selected really do measure that which 
they are purposed to measure.  This concept  encompasses answers  to meaningful  
questions that are posed for obtaining meaningful answers and therefore meaningful 
information  (Faber et al., 2006).  
 
Face validity can be defined as logical validity, which is a simple form of validity 
which can be achieved by subjectively and superficially assessing whether or not the 
test outcome measures result from a meaningful investigation into what they are 
required to measure (Barnett et al., 2015). The term “face value” is appropriate in that 
the questions posed merely skim the surface in order for the researcher to form an 
opinion. This is the easiest form of validity that is sought in research.  Since no 
objective measures are applied, it is the weakest form of validity (Lynn, 1986). 
 
Construct validity refers to an independent variable or construct that is accurately 
defined. An example of an independent variable would be  the leadership style of a 
school principal  with  the sub-scales of that construct  being the various types of 
leadership style (e.g. authoritative, delegative and participatory leadership) (Keenan 
et al., 2008). Construct validity would reflect  whether the items under investigation in 
the test are sound and valid, by employing the statistical technique of factor analysis.  
Each sub-scale should then have a good inter-item correlation which would be 
measured using the bivariate correlation method (Keenan., 2008). 
Criterion validity could also be called concrete validity.  It refers to the extent to 
which a study tool or measure is related to an outcome. Criterion validity can be 
divided into two categories, namely concurrent and predictive validity (Voepel-Lewis 
et al., 2010).    
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Concurrent validity can be defined as a valid comparison between the measure in 
the study and an outcome that is being assessed at the same time, and is 
appropriate when the researcher  uses them the outcome measures in tool 
development and adaptation) (Atkinson et al., 2004). 
 
2.9.2. Reliability  
Reliability in terms of research implies that the results of an investigation would be 
found to be similar if the investigation were to be conducted more than once – at 
various times (repetitively). The term “test-retest reliability” would be appropriate in 
this context. Reliability could also apply to the extent to which the outcome measure 
can be determined but still retain its objective value. The term “inter-rater reliability” 
would be appropriate in this context (Bruton et al., 2000).   
 
A tool or instrument used in an investigation is considered to be reliable when the 
researcher considers the internal constancy of the tool. This can be determined by 
statistically calculating Cronbach’s Alpha or the Intra-class correlation (Binkley et al., 
1999). The inter correlation enables the researcher to assess the items of the 
instrument and to determine whether they are measuring the same construct.  
 
There are various types of reliability that should be considered.  These include the 
following: 
 Inter-rater reliability, also called concordance, is the degree of agreement that 
is found among raters. Inter-rater reliability gives a score indicating the extent of 
homogeneity, as well as the consensus between the raters that is noted by the 
researcher. This measure has been shown to be useful when refining tools given 
to assessors who are deciding whether a particular tool is appropriate for 
measuring a particular variable. The different statistical measures used include 
Cohen’s Kappa and Fleiss‘s Kappa (Gwet, 2014).  
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 Test-retest reliability is the measure of reliability that is calculated and 
determined when a researcher administers the same outcome measuring tool 
twice over a period of time using the inputs (information) from the same 
participants in the study. The scores from the first  and  second data collection 
times can be statistically correlated in order to assess the outcome measure for 
stability over the period of time  between the two data collection times (Kizlik, 
2012). 
 Intra-rater reliability is the degree of agreement found among repeated 
administrations of an investigative or diagnostic test conducted by a single 
person or rater (Bennell et al., 1998).  
 Internal consistency is a measure that notes how a test addresses different 
constructs and comes up with reliable scores. The test-retest method involves 
administering the same outcome measure over  a period of time and then 
comparing  the results obtained from the first  and  second data collection times 
(Binkley et al., 1999) 
 
2.10.  HIV-RELATED DISTAL SENSORY PERIPHERAL NEUROPATHY OUTCOME 
MEASURES 
 
Peripheral neuropathy is one of the common complications of patients with PLHIV 
who are on anti-retroviral drugs (ARVs). The literature has reported on several tools 
that have been used to measure the functional outcomes of such patients who are 
suffering from the associated peripheral neuropathy (Tumusiime et al., 2014).  
 
The Lower Limb Functional Scale (LLFS) and the Lower Extremity Functional Scale 
(LEFS) are the two most commonly used outcome measures for lower extremity 
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function (Gabel.,1999). Outcome measures are the scales or indices that are 
presented to the patients in the sample for them to indicate their assessment of their 
condition.  The completed scales are then interpreted by the researcher in order to 
accurately measure the various areas of interest from which the therapist is 
expecting  a response (Hammond, 2000).  
 
The selection of an outcome measure depends on the requirements of the therapist 
and the type of outcome information that the therapist is interested in  measuring 
(Hammond, 2000). Of paramount importance is the fact that these outcome 
measures must have sound clinometric as well as psychometric properties to ensure 
the validity and reliability of the instrument being used. Furthermore, the outcome 
measures in question should cause no pain or discomfort to the patient or participant 
(Hammond, 2000). The LEFS questionnaire used in this study has previously been 
shown to be reliable, valid and responsive to change (Galantino et al., 2014).   
 
Because the LEFS is a tool  used in investigating musculoskeletal conditions such as 
hip arthritis (Pua et al., 2009) and in joint replacements (Yeung et al., 2009), it was  
used in this study to determine the test–retest reliability of the LEFS outcome 
measure in HIV–related DSPN,   
 
Some screening using other screening tools had been undertaken prior to the main 
test-retest study to select participants for this research project. The screening tools 
used in the initial study included the Brief Peripheral Neuropathy Screening (BPNS), 
as well as the Brief Peripheral Neuropathy Tool. These tools are discussed in the 
sections below. 
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2.11. THE SUITABILITY OF THE BRIEF PERIPHERAL NEUROPATHY SCREEN 
(BPNS) FOR DIAGNOSING DSPN IN HIV/AIDS PATIENTS 
 
The Brief Peripheral Neuropathy Screen (BPNS) was used as the initial screening 
tool to select the participants for this study. Having proved itself to be both reliable 
and valid, and facilitative of self-reporting, it was the tool of choice for this study for 
specifically diagnosing Distal Sensory Peripheral Neuropathy (Cherry et al., 2005). 
Furthermore, this screening tool is able to monitor both objective and subjective 
outcomes which are consistent with peripheral neuropathy, the disease focused on in 
this study.  
 
BPNS has established a reputation for itself in that it has been extensively used in 
research and clinical trial protocols such as in projects undertaken by the AIDS 
Clinical Trial Group (ACTG) (Cherry et al., 2005). The study undertaken by Cherry et 
al. (2005) conclusively pointed out that the BSPN is useful because it includes both 
the signs and symptoms of DSPN and therefore it can be used specifically for 
screening DSPN, which is HIV-related.  
 
Mehta et al. (2011) also used the BPNS in a study of participants receiving ARVs in 
Mombasa, Kenya. The study recommended that doctors should find it easily able to 
integrate BPNS when reviewing HIV patients, especially in resource-limited areas. 
Tumusiime et al. (2014) in their study in Rwanda showed that the BPNS had proved 
to be an easy and reliable tool in a resource-limited environment where participants 
could not afford specialized expensive clinical tests.  It was for these reasons that 
this researcher decided to use the BPNS in this study of Botswana.  It was also used 
in both the pilot study and the main study. 
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Lower Extremity Functional Scale (LEFS) 
The LEFS questionnaire is an outcome measure developed by Binkley et al. (1999) 
and measures lower extremity function in the following areas, namely  ambulation, 
activities of daily living, functional activities and activities that measure strength, 
which  include squatting and standing. The LEFS can be used by clinicians to 
measure patients’ initial functionality, their ongoing progress and their outcomes, as 
well as to set functional goals for the patient. 
 
The LEFS is efficient to administer (five minutes) and to score (one minute), and can 
be applied for research purposes and for clinical decision-making in respect of 
individual patients with musculo-skeletal dysfunction (Binkley et al., 1999). The LEFS 
is a reliable tool and its construct validity is supported by the fact that it compares 
favourably with the SF-36 (Binkley et al., 1999). The sensitivity of the LEFS to detect 
change in function is high (Binkley., 1999). Furthermore, the LEFS demonstrates 
comparable reliability in terms of scale width and maintains high criterion validity. 
Research by Binkley et al. (1999 ) found that the LEFS demonstrates sound 
clinometric properties. 
 
Binkley et al. (1999) developed the LEFS tool to measure various lower extremity 
conditions. With the international classification of function  ICF model as the initial 
guideline,  the development of the tool followed the WHO model, which in itself  
covers  components such as impairment, disability and handicap (World Health 
Organisation, 2005) particularly in the elderly.  
 
The LEFS tool consists of 20 items which measure the level of difficulty in conducting 
the activities of daily living (ADLS). The scores of the instrument are shown as 
follows: 4 =”no difficulty”, 3 = “a little difficulty”, 2 = “moderate difficulty”, 1 = “quite a 
bit of difficulty”, 0 = “unable to perform activity”.  
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The participant is required to rank the scores, with the highest score of 80 being the 
normal function and the lowest  of  0 being no functional activity at all (Binkley et al., 
1999) . These functional scores are categorised as follows, “no difficulty” (80 
points),”a little bit of difficulty” (79-60 points), “moderate difficulty” (59-40 points), 
“quite a bit of difficulty” (39-20), “unable to perform activity” or “extremely difficult” 
(19-0) (Schep et al., 2009).  
 
The two most important reasons or investigating the functional status of the 
participants in the research are listed below:  
 To document the physiotherapeutic outcomes in patients for the purposes of 
research, quality assurance and to establish the appropriate clinical standards; 
and 
 To document the functional outcomes in order to plan and set the treatment goals 
for the successive functional levels for progress and outcomes in respect of 
individual patients (Gabel et al., 2006) .  
 
The LEFS questionnaire is an effective scale for documenting the lower extremity 
function in terms of the reasons mentioned above, as well as the fact that this tool is 
easily administered. Furthermore, the LEFS tends to overcome the barriers that are 
identified when a health status measure is implemented in a clinical practice setting 
(Gabel et al., 2006).  Because of a better understanding in terms of the interpretation 
of the LEFS measurement error and good detection in the case of the score changes, 
the measures of validity and reliability of this tool, as well as its sensitivity to change, 
are sufficient to justify its use at an individual level (Gabel et al., 2006).   
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Comparison between the outcome measure tool, Lower Extremity Functional 
Scale (LEFS) and the other tools  
 
The LEFS is a reliable tool for assessing patients with musculoskeletal disorders. W 
A comparison of this scale with the Health Survey Questionnaire and the Medical 
Outcomes Study 36-item revealed that the construct validity of this tool is good. 
Furthermore, the LEFS compares favourably with the Lower Extremity Functional 
Index (LEFI) in terms of its scale width and its high level of criterion validity. A 
comparison of the LEFI and the LEFS showed that the LEFI performs better than the 
LEFS. It was also found that the response of the LEFI  to change is better, that it 
reveals a low minimal detectable change score (MDC), that it is far superior  in terms 
of internal consistency and  readability, that it has a lower response error as well as a  
faster scoring and  completion time (Gabel et al., 2006). Furthermore, the LEFS is 
more widely used as a tool than the LEFI, but, apart from the fact that the LEFI has 
better clinometric properties,   this researcher chose to use the LEFS.  
 
The LEFS is a tool that has been used to assess and diagnose different medical 
conditions and its test-retest reliability has been shown to be strong. A number of 
studies have been reviewed to assess the results of tests for the LEFS’s reliability, 
validity and internal consistency. Table 2.3, for instance, is a comparison of the test-
retest reliability of the LEFS under the respective medical conditions. Table 2.3 in its 
turn, outlines the studies in terms of the author, year of study, the aims and results of 
the study, and the reliability, validity and internal consistency of this tool and the data 
that were applicable at the time of this research. 
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Table 2.3: Comparison of the Test-Retest Reliability of the LEFS in Terms of the Respective Medical Conditions 
Reference Population   Study design  Aim Key results Reliability Validity Internal 
consistency 
Alcock et 
al. (2012) 
Patients with Acute 
Cruciate Ligament 
(ACL) reconstructive 
surgery 
Mean age: 
29.4±10.6(M) 
29.0(9.6)(F) 
N=45 
Country: Canada 
The repeat test 
measures 
observational 
study design 
 
To describe the pattern 
of change in patients’ 
lower extremity physical 
function after ACL 
reconstructive surgery 
and also to 
estimate the test-retest 
reliability of the LEFs 
Improvement in 
LEFS scores within 
the 7th and 8th week 
of surgery. 
High correlation 
coefficient with test- 
retest reliability 
within four days 
Test retest:  
ICC: 0.90 
SEM: 3.7 
n/a n/a 
Binkley et 
al. (1999) 
Patients with lower 
extremity 
musculoskeletal 
problems 
Mean age: 44±16.2 
Gender: Female=58 
N=107 
The repeat test 
measures 
observational 
study design 
 
To report the 
development process, 
validation, reliability and 
the internal consistency 
of the LEFS 
LEFS is valid and 
reliable for 
measuring physical 
function.  
Test retest:  
R (entire 
sample)=0.94(95% 
lower limit CI=0.89) 
R(Chronic conditions)= 
0.86 (95% lower limit 
CI=.80) 
Construct validity:  
Correlations 
between SF-36 
(Physical function) 
and LEFS, r=0.80 
(95% lower limit 
CI=.73) 
α=0.96 
Kennedy et 
al. (2008) 
Patients after one  
year of total knee 
arthroplasty (TKA) 
N=84 
The repeat  test 
measures 
observational 
study design 
To describe the pattern 
of change in the  lower-
extremity functional 
status of patients after 
total knee arthroplasty 
(TKA) 
LEFS scores 
improved in the first 
26 weeks after 
which improvement 
was limited.  
Test retest: ICC=0.85 
SEM: 3.7 
n/a n/a 
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Yeung et 
al. (2009) 
Patients with lower 
extremity 
musculoskeletal 
problems Gender: 
65.5% female 
N=150 
The longitudinal 
repeat test 
measures  
design 
To determine the test-
retest reliability, 
construct 
validity, and 
responsiveness in 
patients with lower 
extremity 
musculoskeletal 
problems 
The LEFS showed 
good reliability and 
it is valid for  
measuring  
changes in function 
in patients with 
lower extremity 
musculoskeletal 
problems  
ICC= 
0.88 (95% 
CI: 0.74, 0.95). SEM 
=3.5  
points  
 
There was a 
significant 
difference between 
the LEFS scores of 
the respondents 
and non-
respondents.  
w= 653.5, 
P=0.01 
n/a 
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Table 2.3(b):  Comparison of the Test-Retest Reliability of the LEFS in Terms of the Respective Medical Conditions 
Reference Population   Study 
design  
Aim Key results Reliability Validity Internal 
consistency 
Hoogeboom 
et al. (2012) 
Patients  
diagnosed with hip 
or knee 
Osteoarthritis (OA) 
Mean age: 61±11 
Gender: 63% 
Female 
N=106 
Prospective 
study 
 
To evaluate the 
psychometric 
qualities of the 
Dutch LEFS in 
patients  with hip 
or knee OA 
The Dutch version 
of the LEFS has 
good reliability, 
validity and internal 
consistency 
Test retest:  
ICC = 0.86 
 
Construct validity:  
Correlations between 
LEFs and the physical 
function  
Hip, r95%CI: 
0.78(0.69-0.84) 
Knee, r95%CI: 
0.78(0.73-0.83) 
α=0.96 
Lin et al. 
(2009) 
Patients  with 
ankle fracture 
N=306 
Mean age=45.1 
±15.7 
Gender: N=154 
female 
 
Randomized 
controlled 
trial 
To measure 
clinometric 
properties of 
LEFS 
The LEFs is useful 
for measuring and 
monitoring function 
in patients with 
ankle fracture.  
n/a Concurrent validity 
with  
Olerud Molander 
Ankle Score  
Short term:  r=0.80 
Medium: r=0.87 
Correlation with 
walking (r=0.61) and 
stepping (r=0.63)  
Baseline:  
α=0.92 
Short-term 
follow up: 
0.94  
Medium-term 
follow up: 
0.90  
Cacchio et al. 
(2010) 
Patients  with one-
sided lower 
extremity 
dysfunction 
Prospective 
methodo- 
logical study 
of repeated 
To determine the 
measurement 
properties of the 
Italian version of 
the LEFs.  
The Italian version 
of the LEFs showed 
good reliability and 
internal 
consistency.  
Test retest:  
Intra-rater: ICC=0.91, 
95%CI=0.86-0.91 
Construct validity:  
Correlation with the 
physical component of 
SF-36 
α=0.94, 
95%CI=0.91-
0.96 
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Gender: n=136 
Mean age: 
46.7±12.3 
N=250 
measures Inter-rater: ICC=0.89 
95% CI: 0.83- 0.91 
R=0.61 
Pua et al. 
(2009) 
Patients with hip 
OA 
Mean age: 62±10 
Female: 60% 
Country: Australia 
N=100 
Test-retest 
reliability  
To measure 
correlates of 
physical function 
in patients with 
hip OA. 
The LEFs showed 
better point 
estimates in 
measuring physical 
function in adults 
with hip OA. 
Test retest:  
ICC (95%CI): 
0.92 (0.85-0.96) 
Standardized SEM: 
4.5 
Discriminant validity: 
Stronger correlation 
with the physical 
function component of 
the SF-36 
ICC=0.75(0.65-0.85), 
p<0.05 
n/a 
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The studies presented  in Table 2.3 above  all show that the tool LEFS has a high 
test-retest reliability in terms of other medical conditions,  including hip osteoarthritis 
and musculoskeletal dysfunction. 
 
2.12. CONCLUSIONS EMANATING FROM THE LITERATURE REVIEW 
The literature to show that HIV-related Distal Sensory Neuropathy is a major 
neurological complication that has a significant prevalence in patients on ARVs is 
substantial. The neurological impacts that DSPN has on the body include a wide 
range of impairments to the body systems.  However, the major focus of this study is 
on the neurological system.  The side effects of the ante-retroviral drugs tend to 
significantly aggravate the condition of DSPN. There are, however, treatment 
modalities that include drug therapies and non- drug therapies to manage one of 
these side effects, namely, the pain.   
 
The Lower Extremity Functional Scale has proved to be one of the more successful 
and more commonly used a clinical outcome measures for measuring the functional 
capacity of patients with DSPN.  The reason for this is that  it has been shown to be 
reliable and valid in the case of certain medical conditions such as arthritis, hip and 
knee replacements; and hence the need to validate them in HIV-related DSPN. 
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3. CHAPTER THREE: METHODOLOGY 
 
3.1. INTRODUCTION  
Chapter Three explains the research study design, details of the participants, the 
instruments used, the nature of the procedures conducted, and the statistical 
analysis of the data. The instruments and procedures used both in the pilot study and 
the main study are outlined in this chapter. 
 
3.2. STUDY DESIGN 
This is a test-retest study design with a seven-to-ten-day interval between the two 
testing times. 
 
3.3. POPULATION AND SAMPLING 
3.3.1. Source of the Participants 
Six clinics in Gaborone were used from which to collect data. The patients attending 
these clinics were employed in both the public and private sector. They were 
recruited for this research project when they came for their consultations with the 
infectious disease specialists, neurologists, HIV physicians, or when they came to 
collect their anti-retroviral medication.  
 
All of the patients selected for this study had already been diagnosed as HIV-positive 
and were on anti-retroviral therapy. Furthermore, the patients who were included in 
the study were already presenting with symptoms of DSPN in the lower limb areas 
which had been confirmed by the HIV physicians (Cherry et al., 2014). The data 
collection was conducted on two separate occasions, the interval between the two 
being a period of seven months. 
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3.3.2. Sample Size  
The sample size was calculated on the basis of the EPI information version 6 stat for 
population surveys or descriptive study random calculation. An HIV population 
estimated at 3500 with an expected 30% prevalence of DSPN, and a worst 
acceptable prevalence of 40%, was drawn for calculation. Using a 95% level of 
confidence, a sample size of 79 participants was finally obtained (Mohamad., et al 
2013).  
 
3.3.3. Eligibility Criteria 
Inclusion criteria 
 HIV patients on ART with DSPN  
 The male and female participants who attended the clinics selected for this study 
were from both rural and urban areas.  
 The patients were from 18 to 75 years of age.  
 The participants were able to read or undergo a structured clinical interview to 
provide details of their use of ART and to understand the measurement tool used 
in the study.   
 Patients  on different types of ARVs   
 Patients with DSPN, which had been confirmed by the Brief Peripheral 
Neuropathy Screening (BPNS) tool. 
 
Exclusion criteria 
 HIV patients on ART with no symptoms of  DSPN 
 Diabetic patients with DSPN issuing from the diabetes rather than from the ARV 
medication  
 Those who had known injuries to the lower limbs such as fractures and burns  
 Patients who could not understand the questions owing to  mental impairment 
 Patients who were HIV but who were not on ARVs 
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 Patients who were not from Botswana 
 Patients with severe exposed wounds or Kaposi Sarcoma  
 
3.4. ETHICAL CONSIDERATIONS 
Ethical approval was sought from the University of the Witwatersrand’s Human 
Research Ethics Committee (Medical), the ethical clearance number awarded being 
M140496 (See Appendix 6). Additionally, permission to undertake the study was 
sought and obtained from the respective HIV clinics. The ethical approval reference 
number for the hospitals was PMH 5/79 (155) (See Appendix 7). Written informed 
consent from the study participants was obtained before they participated. All   
participants were above the age of 18 years. 
 
3.5. STUDY INSTRUMENTS 
This section describes the instruments used in this study.  They were BPNS, BPNST 
and the LEFS.  
 
3.5.1. Translation of the Language on the Questionnaire 
Some patients could not understand the English language version of the 
questionnaires. As such, the questionnaires were translated into Setswana in a 
manner similar to the presentation by (Tumusiime, 2014). Two independent 
Setswana professional language translators from the University of Botswana were 
commissioned to do this task. The questionnaires were translated and back 
translated to ensure content validity. A focus group comprising of the translators 
three rehabilitation specialists, and this researcher, met to ensure that the translated 
version was in fact a correct interpretation of the original questionnaire and that the 
meaning was the same. No major modifications to suit the cultural background of the 
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participants were needed. (The Setswana translation of the LEFS is presented in 
Appendix 1).   
 
3.5.2. Administration of the Questionnaire 
Brief Peripheral Neuropathy screening (BPNS) 
As explained in Table 3,1 the Brief Peripheral Neuropathy Screening (BPNS) 
questionnaire, presented in both English   and Setswana, was given to the 
participants to complete, (It is presented in Appendix 3 and described in the literature 
review).    
 
Table 3.1: Brief Peripheral Neuropathy Screening Questionnaire (BPNS) 
Completed by the Participants 
Instrument of study Outcome variables to be 
tested 
Procedure 
Brief Peripheral Neuropathy 
Screen Questionnaire 
(BPNS) 
(Appendix 3) 
Indications that the 
participants have at least 
three of the signs and 
symptoms of  peripheral 
neuropathy 
Participants were invited to fill in the 
questionnaire in order to voluntarily 
participate in the study. The 
participants needed to answer “yes” 
to at least three questions in the 
screening questionnaire before they 
were included in the study. 
 
Brief Neuropathy Screening Tool (BPNST) 
The brief neuropathy screening tool was also given to patients to ensure that only 
those with sensory neuropathy were identified for the study. Table 3.1 outlines the 
outcome variables and procedure for the BPNST. 
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Table 3.2: Brief Neuropathy Screening Tool (BPNST)  
Instrument of study Outcome variables to be tested Procedure 
(BPNS) 
Brief Peripheral 
Neuropathy Screen Tool 
(BPNST). 
(Appendix 5) 
. 
Intensity of the symptoms of 
peripheral neuropathy recorded 
from the research candidates. 
The purpose of the Brief Peripheral 
Neuropathy Screening Tool was to 
verify the existence, if any, of 
symptoms such as pain which could 
be burning, sharp, pins and 
needles, stabbing or aching, 
muscular tightness due to cramps, 
tingling sensations and numbness. 
The Brief Peripheral Neuropathy 
Screening Tool was used when 
screening for Distal Sensory 
Peripheral Neuropathy by the 
physician.  
Confirmation of the diagnosis of 
peripheral neuropathy was 
made possible through the 
physical assessment by the 
physician of symptoms such as 
pain and vibration sensation. 
The severity of the pain was 
noted through the usage of the 
visual analogue scale for pain 
severity. The physician used the 
128 Hz tuning fork to determine 
vibration sensation and the 
duration of the tuning fork 
vibration was noted. Tendon-
Achilles tapping was used to 
assess the reflexes of the ankle 
joint. 
 
 
The Lower Extremity Functional Scale (LEFS) 
The LEFS was used to assess the level of lower limb function in patients that were 
HIV positive and presenting with DSPN. Functionality was measured by assessing 
the difficulty experienced in a range of activities such as doing housework, 
involvement in hobbies, walking, standing, running, and activities of daily living 
(Binkley et al., 1999). Each of the activities was assessed using a Likert scale of 0-4. 
 
The Lower Extremity Functional Scale (LEFS) (in Appendix 1, and described in the 
literature review), in both English and Setswana, was given to the participants 
(Appendix 1) to complete. Those patients who could not read and write were assisted 
by a trained interpreter.  
 
The LEFS was used to establish the functional ability of the patients with Distal 
Sensory Peripheral Neuropathy (DSPN). The procedure involved offering the LEFS 
tool to patients after they had been screened for DSPN symptoms by the Brief 
Peripheral Neuropathy Screen Questionnaire (BPNS) while they were in the waiting 
area. 
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Thereafter each patient was offered a private room to complete the questionnaire. 
This procedure was maintained for every patient to ensure that the conditions were 
consistent and to reduce the possibility of random errors slipping in.  This same 
procedure was followed when they came in to the clinic seven days later, the only 
exception being that they did not again fill in the Brief Sensory Neuropathy Screening 
questionnaire.  Most patients were given a date for the retest whereas the remainder 
would routinely return for physiotherapy or a doctor’s appointment. 
 
3.6. PILOT STUDY 
A pilot study was conducted on HIV patients with DSPN. The objective of the pilot 
study was:  
 to determine the feasibility of conducting the study  
 to determine any unforeseen challenges that might arise in the course of the 
main study  
 to familiarize the researcher with the translated questionnaires and the study 
process, and to estimate the time by which the  testing sessions would have been 
completed.  
3.6.1. Pilot Study Procedure 
The pilot study was conducted over a period of three weeks. Fifteen participants 
were recruited as the sample population to participate in the pilot study. It was 
decided that a sample size of at least 10% of the estimated sample would be 
sufficient to conduct a pilot study (Leedy and Ormrod, 2012).  
 
The participants were screened on the basis of the BPNS questionnaire and 
confirmed as having DPSN.  Five participants were recruited from the neurology unit 
of one clinic, and ten participants from an HIV infectious disease unit. The neurologist 
then confirmed the peripheral neuropathy diagnosis in each case. 
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The participants were then given the LEFS to complete on their own and were invited 
back for the second data collection time conducted using the LEFS tool after seven 
to ten days. The test-retest reliability value was subsequently calculated, an analysis 
made of the duration of the time taken, and any problems were identified, assessed 
and noted. The results and the discussion of the pilot study are discussed below. 
 
Results of the pilot study 
Fifteen patients participated in the pilot study.  
 
Feasibility 
It was possible and efficient to recruit the participants after screening with the Brief 
Peripheral Neuropathy Screening Questionnaire. The Setswana (translated version) 
and the English version of the LEFS were used. The language used was simple and 
easy to understand so that there was no need to alter any language terminology in 
either of the versions. The process of translating and back translating reduced the 
possibility of any errors creeping in.  As such, the participants were able to answer 
the questions on the LEFS without any difficulty.  
 
They reported that they understood the translated version and were able to answer 
all the questions without difficulty. None of the participants requested further 
explanation. During the course of the pilot study, this researcher managed to adjust 
punctuation and logistical issues that had not been foreseen before the study 
commenced.  
 
Once the questionnaire had been completed by the patients and the relevant data 
collected, descriptive statistical analysis could be carried out to outline the patients’ 
responses in terms of frequencies and the mode for each Likert score. Test-retest 
reliability using the Spearman’s rank order correlation test (rho) was calculated to 
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assess the use of this tool (questionnaire) for testing for reliability, and a correlation 
of rs = 0.7-1.00, p<0.05 was obtained.  
 
The detailed results for each of the items listed in the questionnaire are outlined in 
Appendix 6.  
 
One of the difficulties was that some participants could not afford to come for the 
second session owing to financial issues.  As such, their data could not be used.  
Measures were taken in the main study, to ensure that the participants completed 
their assessments on both occasions. (The measures taken are explained below.) 
There was no significant change between the respective procedures adopted for the 
pilot study and the main study.  Therefore, the results were included in the main 
study.  
 
3.7. MAIN STUDY 
This entire study was conducted over a period of seven months.  Both the pilot study 
and the main study were completed over this period. This researcher used six clinics 
in Gaborone’s urban hospitals, a combination of both private and government 
institutions, to select a sample population. 
 
The initial number of the HIV patients invited for the study was 320. They were all 
HIV patients who had arrived at the clinics for consultations and to collect their ART 
medications during the time period in which the study was conducted and had 
accepted the invitation to participate in the study.  
 
They were given the BPNS questionnaire to complete but only 84 managed to qualify 
as participants for the entire duration of the research process. Once the BPNS 
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questionnaires had been completed by the participants, they were referred to the 
physician for his BPNS tool assessment of the efficacy of the BPNS questionnaire as 
a diagnostic tool.    
 
Once the neurologist/physician had confirmed the DSPN  diagnosis for each of the 
participants , the demographic and clinical information for each patient was  collected 
from  the neurologist’s/physician’s checklist1 for peripheral neuropathies The 
neurologist/physician then recorded the severity of the DSPN using the Brief 
Peripheral Neuropathy Screening tool in Appendix 5. 
 
3.7.1. Objectives 
The objectives of this study were as follows: 
 To establish the test-retest reliability of the LEFS in the measurement of lower 
limb function in HIV-related DSPN in Botswana. 
 To determine the internal consistency of the LEFS for lower limb function in HIV-
related DSPN in Botswana. 
 To determine the construct validity of the LEFS in participants with DSPN 
 To describe the demographic and clinical characteristics of HIV patients with 
DSPN in Botswana. 
 
3.7.2. Procedure 
An invitation to participate was extended to the participants in this study. Those who 
answered “yes” to three or more questions in the BPNS questionnaire qualified to 
see the physician for subsequent screening. Those who were selected were 
requested to complete the LEFS questionnaire for the first time on their own. Finally, 
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they were requested to once again complete the same LEFS questionnaire when it 
was administered seven to 10 days after the initial administration.  
 
Individuals who had challenges with reading and writing were assisted by a trained 
translator who helped them to use the translated questionnaire to complete the 
BPNS questionnaires. The translator played an important role in explaining and 
clarifying any possible misconceptions that the participants might have had.  In order 
to ensure that the participants’ information remained private and confidential, the 
process of collecting all the data for the study and of recording all the study 
procedures took place in a secluded room.  
 
The same procedure used in the pilot study was repeated in the main study. To 
ensure that the participants returned for the second measurement and to minimise 
financial difficulties, patients were:   
 Given a return date 
 Contacted telephonically for follow-ups, and where necessary, visited in their 
homes. 
 
3.7.3. Demographic Information 
The demographic data and clinical information were collected from the physician’s 
checklist for peripheral neuropathies (Appendix 4). The demographic information 
collected included details pertaining to marital status, sex, the age of the participants, 
the level of education attained, the type of job that they held, other HIV-related issues 
such as the CD4+ count, the duration of time  on treatment, the HIV- stage in which 
they found themselves, and other comorbidities.  
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One of the critical components considered when recording the personal information 
was to take note of the types of antiretroviral medication administered to the 
participants.  
 
3.7.4. Data Analysis 
To ensure confidentiality, each research participant was awarded a different but 
unique anonymous code.  The initial information pertaining to the participant was 
recorded on an Excel spreadsheet.  The information was then converted and 
transferred into the Statistical Software Programme for Data Analysis (SPSS version 
20). Table 3.3 below outlines the statistical tests used and the rationale for the tests.  
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Table 3.3:  Outcome Measure, Statistical Test and Rationale 
Outcome  Outcome Measure  Statistical Test  Rationale 
Demographics Age, gender, level of 
education attained, marital 
status, occupation and HIV 
clinical information 
Descriptive statistics of 
means, standard deviation, 
frequencies and percentages 
Measurements of central 
tendencies were used to 
summarize the data (Daniel, 
1995). 
DSPN Prevalence and severity Descriptive statistics of 
frequencies and percentages 
Measurements of central 
tendencies were used to 
summarize the data (Daniel, 
1995). 
Measure of 
association 
between the 
diagnosis of 
DSPN and 
socio-
demographic  
attributes 
Age, gender, level of 
education attained, marital 
status, occupation and HIV 
clinical information 
Fischer’s Exact Test Fischer’s Exact Test was 
used to measure the 
association between 
categorical variables (Upton, 
1992).  
LEFS  Mean scores and specific 
scores for Tests 1 and 2. 
Descriptive statistics of 
means, standard deviations, 
frequencies and percentages 
Measurement of central 
tendencies were used to 
summarize the data (Daniel, 
1995).  
Test-retest reliability Spearman’s rank order 
correlation coefficient 
Spearman’s rank order 
coefficient was used to 
measure the reliability of 
ordinal categorical variables 
(Binkley, 1999). 
Standard error of 
measurement (SEM). 
SEM = SDdifference/√2 
 
(SDdifference is the standard 
deviation of the mean 
change score between Tests 
1 and 2) 
 
Measurement bias (Bland 
Altman Test, One sample T-
Test, linear regression) 
Determination of the type of 
error (random or systematic) 
(Watson, 2005). 
Internal consistency Intra-class coefficient (ICC) ICC was used to measure 
internal consistency of 
categorical variables 
(Watson, 2005). 
Construct validity Factor analysis 
(Unrotated and varimax 
rotated) 
To assess the construct of 
the different components of 
the tool (Binkley, 1999). 
 
Descriptive statistics, namely frequencies, means, modes, standard deviations and 
percentages were used to summarise the demographic data. The level of sensory 
neuropathy was described in terms of three categories. These categories were 
obtained by using the Visual Analogue Scale (VAS) and were classified as mild 
(grade 1) when VAS =1-3, as moderate (grade 2) when VAS = 4-6 and as severe 
(grade 3) when Vas= 7-10. These three categories were descriptively calculated and 
tests for the respective associations between these three categories and the 
demographic variables such as age, gender, marital status, and HIV clinical stage, 
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duration of the HIV infection and of the administration of anti-retroviral drugs were 
conducted using Fischer’s Exact Test. 
 
As the variables were categorical and ordinal, Spearman’s rank order correlation 
coefficients and the intra-class correlations were used to establish the test-retest 
reliability value and the internal consistency of the LEFS, The Spearman’s correlation 
coefficients were classified according to their significance levels so that a strong 
correlation was assessed as rho ≥ 0.7, moderate at rho < 0.7 ≥ 0.5, and a weak 
correlation was assessed as rho ≤ 0.5 (Tumusiime et al., 2014). 
 
The alpha level was set at p< 0.05. Intra-class correlations were calculated on SPSS 
version 20 to assess the internal consistency of the LEFS when used among 
participants with HIV-related DSPN. The factor analysis and the measurement error 
were calculated using the Bland Altman test and the SEM was calculated.  
  
3.8. CONCLUSION 
The participants were selected from the six clinics in Gaborone. The tools that were 
used in the study were the BPNS, the physician’s checklist for peripheral neuropathy 
- also containing demographic and clinical information, the BPNST recording the 
severity of DSPN, and the LEFS.  
 
Important information relating to the participants’ demographics was obtained and 
recorded by the physician, neurologist or HIV doctor. The scores obtained for the 
LEFS were recorded and the test–retest reliability of the LEFS among HIV positive 
patients on ART and with DSPN was calculated.  
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Spearman’s rank order correlation coefficient and the Intra-class coefficients (ICC) 
were used to determine the test-retest reliability level and for internal consistency 
respectively. The Fischer Exact Test was used for measuring the level of association 
between the demographic variables pertaining to the patients and the three 
categories in terms of the severity of the DSPN that they were experiencing. The 
varimax, determined by factor analysis, and the measurement error were calculated 
using the Bland Altman test and the SEM was calculated. 
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4. CHAPTER FOUR: RESULTS 
 
4.1. INTRODUCTION 
This chapter presents the results of the main study. The main aim in this research 
study was to determine the test-retest reliability of the LEFS in HIV-diagnosed 
patients with DSPN who were on ARVs. The results in this chapter are presented 
under the following headings and in the following order:  
a. Participants recruited 
b. Demographic and clinical information pertaining to  the participants 
 Severity grading of Distal Sensory Peripheral Neuropathy 
 Association between LEFS measures and the severity grading of DSPN 
 Association between socio-demographic variables and severity grading of 
DSPN 
c. Test-retest reliability of the LEFS 
 Frequencies of the first response and the second response. 
 Spearman’s correlation coefficients for the means of LEFS between  Test 
One and Test Two respectively 
 Measurement of error 
d. Internal consistency of the LEFS in HIV-related DSPN participants 
e. Construct validity of the LEFS 
f. Conclusions 
 
4.2. PARTICIPANT RECRUITMENT 
A total of 320 patients were screened for potential recruitment for the study, but only 
84 (26.3%) of the overall screened patients met the inclusion criteria to determine the 
sample size.  Figure 4.1 below illustrates the process for recruiting participants.  
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Figure 4.1:  Source of the Patients from the Six Clinics and the Centres 
 
A total of 320 patients were screened and 84 met the criteria of the BPNS test and 
completed the testing on both occasions. 
 
4.2.1. Demographic Information Pertaining to the Participants 
Table 4.1 below outlines the demographic data pertaining to the participants in the 
study.   
  
Total number screened  
(320 participants)
Gaborone HIV CLINICS 
Total number qualifying for 
the study: 
n = 84
PRINCESS MARINA GVT 
HOSPITAL:
FOUR CLINICS 
n=64
INFECTIOUS DISEASE 
CENTRE AND CLINIC
n=44
NEUROLOGY AND OUT 
PATIENT CLINIC 
n=20
BOKAMOSO PRIVATE HIV 
INFECTION HOSPITAL: 
TWO CLINICS 
n=20.
NEUROLOGISTS AND 
PHYSICIANS
n=20
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Table 4.1: Demographic Attributes of the Patients in the Study (n=84) 
Attribute n (%) 
Gender  
Females 59 (70.2%) 
Males 25 (29.8%) 
Age group  
<30 years 8(9.5%) 
31 – 40 years 27 (32.1%) 
41 – 50  years 24 (28.6%) 
<51 years 25 (29.8%) 
Mean age, (SD) 38(±13.0) 
Marital status  
Single 56 (66.7%). 
Married 12 (14.3%). 
Divorced 2 (2.4%). 
Separated 2 (2.4%). 
Widow/Widower 4 (4.8%) 
Cohabitation. 8 (9.5%) 
Level of Education  
Tertiary education 13 (15.5%) 
Secondary education (Form 3-6). 13 (15.5%) 
Secondary education (Form 1-3) 27 (32.1%) 
Primary education 25 (29.8%) 
Nil (did not attend  school) 6 (7.1%) 
Occupation  
Public (Government) service 12 (14.3%) 
Peasant (farmer or livestock farmer) 3 (3.6%) 
Self-employed (businessman) 13 (15.5%) 
Private organisation (NGO, bank, insurance company, etc.) 26 (31.0%) 
Unemployed. (have not had a job for the past three  months) 20 (23.8%) 
Any other piece jobs (i.e temporary jobs) 10 (11.9%) 
 
The mean age of the participants was 38 ± (13.0) years and 70.2% (59) were 
females. The majority of the participants were single (66.7%), had at least some form 
of secondary education (63.1%) and were employed (64.4%).  
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4.2.2. HIV-Related Information 
This section shows the results of the HIV information of the participants with respect 
to the year of diagnosis and the duration of the ARV therapy. Table 4.2 outlines the 
HIV- related information pertaining to the participants.  
 
Table 4.2:  HIV-related Information Pertaining to the Participants (n=84) 
HIV information n (%) 
Duration of time since diagnosis of HIV  
1-6 months 2 (2.4%) 
6-12 months 2 (2.4%) 
1-3 years 5 (6.0%) 
4-6 years 9 (10.7%) 
7-9 years 20 (23.8%) 
10-15 years 40 (47.6%) 
>15 years 6 (7.1%) 
Length of time the patient has been on ART  
1-6 months 4 (4.8%) 
6-12 months 2 (2.4%) 
1-3 years 11 (13.1%) 
4-6 years 7 (8.3%) 
7-9 years 20 (23.8%) 
10-15 years 32 (38.1%) 
>15 years 8 (9.5%) 
Type of ARV treatment  
Travuda. 6 (7.1%) 
Alluvia. 3 (3.6%) 
Nevirapin. 1 (1.2%) 
Combined treatment( two to three different drugs) 62 (73.8%) 
Atripla. 11 (13.1%) 
Teevir. 1 (1.2%) 
Clinical stage of HIV infection  
Stage 1* 5 (6.0%) 
Stage 2** 5 (6.0%) 
Stage 3*** 39 (46.4%) 
Stage 4**** 35 (41.7%) 
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More than half of the participants (53.7%) were diagnosed with HIV more than 10 
years ago and 47.6% had been on ARVs for at least 10 years. Most of the 
participants were in Clinical Stage 3 (46.4%) and Stage 4 (41.7%) of the disease. All 
the participants in this study reported sensory neuropathy, and the frequency of 
DSPN and the severity grades for DSPN for this sample are reported in Table 4.3. 
 
Table 4.3:  Diagnosis and the Grade of Severity of Distal Sensory Peripheral 
Neuropathy  
Grading of DSPN n % 
Mild  (grade 1) 25 29.8 
Moderate (grade 2) 45 53.6 
Severe (grade 3) 14 16.7 
Total 84 100 
 
The results of the DSPN assessment showed that more than half (53.6%) of the 
participants were in the moderate range of sensory neuropathy (grade 2). The grade 
of sensory neuropathy was tested for its association with socio-demographic factors 
to obtain a better understanding of the participants presenting with this condition. 
 
Table 4.4:  LEFS Measures and the Grade of Severity of DSPN   
 Measure 1 LEFS Measure 2 LEFS 
DSPN severity Mean SD Mean SD 
Grade 1 65.60 16.59 64.4 17.35 
Grade 2 62.62 19.95 61.22 20.77 
Grade 3 60.71 20.00 51.00 19.87 
 
The correlation between the LEFS and the severity of DSPN was established on the 
basis of Spearman’s correlation test and showed an inverse relationship (r=-0.22, 
p<0.05).  
 
Table 4.5 shows the association between the socio-demographic variables and the 
grade of severity of sensory neuropathy. 
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Table 4.5: Association between Socio-Demographic Variables and the 
Grade of Severity of Sensory Neuropathy 
Variable  Fischer’s Exact Test 
Age 0.68 
Gender 0.28 
Marital status 0.37 
HIV: clinical stage 0.26 
ART: duration 0.42 
HIV infection: duration from the time of diagnosis 0.04 
 
The duration of the HIV infection from the time of diagnosis was found to be the only 
socio-demographic variable  that showed a significant association with the grade of 
severity of sensory neuropathy (p<0.05).  
 
4.2.3. Frequency of the LEFS Response: Test 1 and Test 2 
Tables 4.6 and 4.7 below outline the results of the response of the participants to 
specific questions relating to the LEFS.  
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Table 4.6:  LEFS Frequencies for Test 1 
Item 
Functional activities, 
n (%) 
Extremely 
difficult 
Considerably  
difficult 
Moderate 
Slightly  
difficult 
No 
difficulty 
a 
Any of the usual work, 
housework or school 
activities 
4(4.8) 5(6.0) 8(9.5) 15(17.9) 52(61.9) 
b 
Your usual hobbies, 
recreational or sporting 
activities 
8(9.5) 4(4.8) 8(9.5) 12(14.3) 52(61.9) 
c 
Getting in and out of the 
bath 
2(2.4) 4(4.8) 6(7.1) 8(9.5) 64(76.2) 
d Walking between rooms 2(2.4) 3(3.6) 4(4.8) 4(4.8) 71(84.5) 
e Putting on shoes or socks 1(1.2) 3(3.6) 8(9.5) 5(6.0) 67(79.8) 
f Squatting 12(14.3) 6(7.1) 6(7.1) 9(10.7) 51(60.7) 
g 
Lifting an object, like a bag 
of groceries, from the floor 
1(1.2) 6(7.1) 8(9.5) 6(7.1) 63(75.0) 
h 
Performing light activities 
around your  home 
2(2.4) 1(1.2) 7(8.3) 10(11.9) 64(76.2) 
i 
Performing heavy duties 
around your home 
12(14.3) 6(7.1) 9(10.7) 14(16.7) 43(51.2) 
j 
Getting in and out of the 
car 
2(2.4) 4(4.8) 5(6.0) 7(8.3) 66(78.6) 
k Walking  for two  blocks 3(3.6) 3(3.6) 7(8.3) 9(10.7) 62(73.8) 
l Walking for a mile. 10(11.9) 4(4.8) 11(13.1) 13(15.5) 46(54.8) 
m 
Going up or down 10 stairs 
(about one flight of stairs). 
9(10.7) 5(6.0) 11(13.1) 17(20.2) 42(50.0) 
n Standing for one hour. 16(19.0) 2(2.4) 21(25.0) 8(9.5) 37(44.0) 
o Sitting for one hour. 6(7.1) 4(4.8) 6(7.1) 9(10.7) 59(70.2) 
p Running on even ground. 15(18.1) 4(4.8) 18(21.7) 7(8.4) 39(47.0) 
q 
Running on uneven 
ground. 
19(22.6) 2(2.4) 21(25.0) 11(13.1) 31(36.9) 
r 
Making sharp turns while 
running fast. 
18(21.4) 3(3.6) 15(17.9) 10(11.9) 38(45.2) 
s Hopping. 14(16.7) 4(4.8) 10(11.9) 11(13.1) 45(53.6) 
t Rolling over in bed. - - - 2(2.4) 82(97.6) 
(Extremely difficult 0 – Not difficult 4) 
 
As shown in Table 4.6 above, more than half of the participants had no difficulty in 
performing each of the following activities in Test 1:- getting in and out of the bath, 
walking between rooms, putting on shoes or socks. 
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Table 4.7:   LEFS frequencies for Test 2 
 
Item 
 
Functional activities, n 
(%) 
Extremely 
difficult 
Considerably  
difficult 
Moderate 
Slightly  
difficult 
No 
difficulty 
a 
Any of the usual work, 
housework or school 
activities 
4(4.8) 5(6.0) 11(13.1) 21(25.0) 43(51.2) 
b 
Your usual hobbies, 
recreational or sporting 
activities 
7(8.3) 6(7.1) 7(8.3) 14(16.7) 50(59.5) 
c 
Getting in and out of the 
bath 
2(2.4) 7(8.3) 5(6.0) 11(13.1) 59(70.2) 
d Walking between rooms 2(2.4) 4(4.8) 10(11.9) 6(7.1) 62(73.8) 
e Putting on shoes or socks 1(1.2) 5(6.0) 9(10.7) 7(8.3) 62(73.8) 
f Squatting 11(13.1) 6(7.1) 7(8.3) 15(17.9) 45(53.6) 
g 
Lifting an object, like a bag 
of groceries, from the floor 
1(1.2) 9(10.7) 9(10.7) 8(9.5) 57(67.9) 
h 
Performing light activities 
around your  home 
2(2.4) 3(3.6) 8(9.5) 16(19.0) 55(65.5) 
i 
Performing heavy duties 
around your home 
12(14.3) 6(7.1) 12(14.3) 18(21.4) 36(42.9) 
j 
Getting in and out of the 
car 
3(3.6) 4(4.8) 8(9.5) 13(15.5) 56(66.7) 
k Walking for two  blocks 4(4.8) 4(4.8) 9(10.7) 13(15.5) 54(64.3) 
l Walking for a mile. 10(11.9) 7(8.3) 14(16.7) 18(21.4) 35(41.7) 
m 
Going up or down 10 
stairs (about one flight of 
stairs). 
9(10.7) 7(8.3) 13(15.5) 20(23.8) 35(41.7) 
n 
Standing for one hour. 
 
18(21.4) 4(4.8) 18(21.4) 10(11.9) 34(40.5) 
o Sitting for one hour. 7(8.3) 7(8.3) 5(6.0) 15(17.9) 50(59.5) 
p Running on even ground. 15(17.9) 5(6.0) 18(21.4) 7(8.3) 39(46.4) 
q 
Running on uneven 
ground. 
18(21.4) 2(2.4) 21(25.0) 12(14.3) 31(36.9) 
r 
Making sharp turns while 
running fast. 
18(21.4) 3(3.6) 15(17.9) 12(14.3) 36(42.9) 
s Hopping. 14(16.7) 5(6.0) 10(11.9) 12(14.3) 43(51.2) 
t Rolling over in bed. 2(2.4) 7(8.3) 7(8.3) 3(3.6) 65(77.4) 
 
As outlined in Table4.7 above, more than half of the participants had no difficulty in 
performing each of the activities in Test 2: getting in and out of the bath, walking 
between rooms, putting on shoes or socks, etc. 
 
4.2.4. Test–Retest Reliability of the LEFS 
The total mean score for the LEFS was calculated as per the instructions given by 
Binkley et al (1999). The results are shown in Table 4.8. 
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Table 4.8: Total Mean Scores for the First and Second Data Collection 
Times of the LEFS 
 N Minimum Maximum Mean SD SEM 
Mean1 84 11 80 63.19 18.86 
4.88 
Mean2 84 8 80 60.46 19.94 
 
Table 4.9 below shows the results of the Spearman’s rank order correlation test to 
determine the test-retest reliability of the LEFS.  
 
The overall total mean score for Test 1 and Test 2 of the LEFS shows a mean value 
ranging from 60.46 to 63.19, with a standard deviation of 18.86 to 19.94. The 
correlation coefficient of the LEFS for the first and second data collection times is 
high, namely an rs value of 0.92 and a p value of <0.001. 
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Table 4.9: Spearman’s Correlation Coefficients for the First and Second 
Data Collection Times for the LEFS 
Item Functional activities 
First data 
set 
(Mean ± SD) 
Second  
data set 
(Mean± SD) 
 Spearman 
(rs) 
p-value 
A 
Any of the usual work, 
housework or school 
activities 
3.26 ± 1.15 3.12 ± 1.15 
 
0.80 
<0.001 
B 
Your usual hobbies, 
recreational or sporting 
activities 
3.14 ± 1.33 3.12±1.31 
 
0.95 
<0.001 
C 
Getting in and out of the 
bath 
3.52 ± 0.99 3.4±1.08 0.89 <0.001 
D Walking between rooms 3.65 ± 0.91 3.45±1.03 0.74 <0.001 
e Putting on shoes or socks 3.6 ± 0.89 3.48±0.99 0.86 <0.001 
f Squatting 2.96 ±1.51 2.92±1.45 0.94 <0.001 
g 
Lifting an object, like a bag 
of groceries, from the floor 
3.48 ±1.01 3.32±1.11 0.84 <0.001 
h 
Performing light activities 
around your  home 
3.58 ±0.88 3.42±0.97 0.79 <0.001 
i 
Performing heavy duties 
around your home 
2.83 ±1.48 2.71±1.44 0.91 <0.001 
j 
Getting in and out of the 
car 
3.56 ±0.97 3.37±1.07 0.73 <0.001 
k Walking for two blocks 3.48 ±1.04 3.3±1.14 0.82 <0.001 
l Walking for a mile. 2.96 ±1.40 2.73±1.39 0.77 <0.001 
m 
Going up or down 10 
stairs (about one flight of 
stairs). 
2.93 ±1.36 2.77±1.36 0.84 <0.001 
n Standing for one hour. 2.57±1.53 2.45±1.57 0.92 <0.001 
o Sitting for one hour. 3.32 ±1.23 3.12±1.32 0.80 <0.001 
p Running on even ground. 2.61±1.55 2.6±1.55 0.99 <0.001 
q 
Running on uneven 
ground. 
2.39±1.55 2.43±1.53 0.98 <0.001 
r 
Making sharp turns while 
running fast 
2.56±1.59 2.54±1.58 0.97 <0.001 
s Hopping 2.82±1.53 2.77±1.53 0.97 <0.001 
t Rolling over in bed 3.98±0.15 3.45±1.10 0.36 <0.001 
 Total Mean 63.19±18.86 60.46±19.94 0.92 <0.001 
 
The results of the test-retest reliability using the Spearman’s  rank order correlation 
coefficient  to show the association between the data for the first and second 
collection times was found to be  strong  (rs=0.74-0.99). All functional activities 
showed strong and significant correlations between the first and  second data 
collection times with the exception of  item ‘t’ (Rolling over in bed), which showed a 
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weak correlation between the first and second collection times (rs = 036, p<0.001), 
as shown in Table 4.10 above.  
 
4.2.5. Internal Consistency of the LEFS in HIV Patients with Distal Sensory Peripheral 
Neuropathy 
Table 4.10 below outlines the results pertaining to the internal consistency using the 
intra- class coefficient of the LEFS for Tests 1 and 2. 
 
Table 4.10: Internal Consistency of Measures 1 and 2 
 ICC 95%CI Significance 
Measure 1 0.96 0.95-0.97 0.00 
Measure 2 0.96 0.95-0.97 0.00 
 
The LEFS showed a high internal consistency, ICC=0.96 for both Tests 1 and 2, and 
a 95% consistency Index (CI) of 0.95 - 0.97.  
 
4.2.6. Construct Validity 
The construct validity variance values are presented in Tables 4.11 and 4.12 below:  
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Table 4.11: Factor Loading for LEFS in Test 1 
 Questions/Items 
Initial 
eigenvalues 
%variance 
Sums of squared 
loadings 
%variance 
Rotated 
sums of squared 
loadings  
%variance 
Q1 Any of the usual work, housework or school activities 58.70 58.70 35.24 
Q2 Your usual hobbies, recreational or sporting activities 7.80 7.80 30.75 
Q3 Getting in and out of the bath 5.11 5.11 5.62 
Q4 Walking between rooms 4.22 
  
Q5 Putting on shoes or socks 3.37 
Q6 Squatting 3.04 
Q7 Lifting an object, like a bag of groceries, from the floor 2.74 
Q8 Performing light activities around your  home 2.48 
Q9 Performing heavy duties around your home 2.14 
Q10 Getting in and out of the car 1.80 
Q11 Walking for two  blocks 1.52 
Q12 Walking for a mile 1.48 
Q13 Going up or down 10 stairs (about one flight of stairs) 1.34 
Q14 Standing for one hour 0.93 
Q15 Sitting for one hour 0.86 
Q16 Running on even ground 0.76 
Q17 Running on uneven ground 0.65 
Q18 Making sharp turns while running fast. 0.48 
Q19 Hopping. 0.32 
Q20 Rolling over in bed. 0.27 
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Table 4.12:  Factor Loading for LEFS in Test 2 
 Questions/Items 
Initial eigenvalues 
%variance 
Sums of 
squared 
loadings 
%variance 
Rotated 
sums of squared 
loadings 
%variance 
Q1 Any of the usual work, housework or school activities 60.05 60.05 37.47 
Q2 Your usual hobbies, recreational or sporting activities 8.38 8.38 30.97 
Q3 Getting in and out of the bath 4.52 
  
Q4 Walking between rooms 3.47 
Q5 Putting on shoes or socks 3.18 
Q6 Squatting 2.93 
Q7 Lifting an object, like a bag of groceries, from the floor 2.65 
Q8 Performing light activities around your  home 2.35 
Q9 Performing heavy duties around your home 2.09 
Q10 Getting in and out of the car 1.64 
Q11 Walking for two blocks 1.59 
Q12 Walking a mile 1.47 
Q13 Going up or down 10 stairs (about one flight of stairs) 1.26 
Q14 Standing for one hour 1.10 
Q15 Sitting for one hour 0.89 
Q16 Running on even ground 0.76 
Q17 Running on uneven ground 0.66 
Q18 Making sharp turns while running fast 0.41 
Q19 Hopping. 0.35 
Q20 Rolling over in bed. 0.26 
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Tables 4.11 and 4.12 above are outlines of the results of the factor analysis for Tests 
1 and 2. The factor analysis results show that the items for both the rotated and the 
unrotated components for Test 1 are loaded on Questions 1 to 3. The factor analysis 
results for Test 2 show that the items for both the rotated and the unrotated 
components are loaded on Questions 1 to 2.  
 
Tables 4.13 and 4.14 below show the rotated and unrotated extracted components of 
the factor analysis respectively. 
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Table 4.13:  Factor Analysis Coefficient for the Specific Items within the 
Split Components (Rotated) 
  Factor analysis coefficient 
  Test 1 Test 2 
 Questions/Items 1 2 3 1 2 
Q1 
Any of the usual work, 
housework or school activities 
0.77 0.43 -0.06 0.76 0.40 
Q2 
Your usual hobbies, recreational 
or sporting activities 
0.67 0.43 0.05 0.53 0.45 
Q3 Getting in and out of the bath 0.84 0.28 0.06 0.81 0.30 
Q4 Walking between rooms 0.86 0.18 0.12 0.81 0.19 
Q5 Putting on shoes or socks 0.61 0.21 0.22 0.75 0.12 
Q6 Squatting 0.40 0.75 -0.01 0.37 0.75 
Q7 
Lifting an object, like a bag of 
groceries, from the floor 
0.63 0.39 0.03 0.73 0.34 
Q8 
Performing light activities around 
your  home 
0.76 0.28 -0.01 0.68 0.42 
Q9 
Performing heavy duties around 
your home 
0.67 0.47 0.02 0.59 0.50 
Q10 Getting in and out of the car 0.80 0.32 0.05 0.76 0.39 
Q11 Walking for two  blocks 0.54 0.49 0.17 0.57 0.51 
Q12 Walking for a mile 0.63 0.43 0.03 0.70 0.36 
Q13 
Going up or down 10 stairs 
(about one flight of stairs) 
0.55 0.63 -0.09 0.51 0.63 
Q14 Standing for one hour 0.48 0.68 0.17 0.57 0.61 
Q15 Sitting for  one hour 0.59 0.51 0.14 0.71 0.41 
Q16 Running on even ground 0.24 0.90 0.05 0.22 0.89 
Q17 Running on uneven ground 0.28 0.87 0.03 0.28 0.87 
Q18 
Making sharp turns while 
running fast 
0.32 0.85 0.17 0.31 0.86 
Q19 Hopping 0.39 0.82 0.08 0.32 0.85 
Q20 Rolling over in bed 0.10 0.10 0.96 0.69 0.30 
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Table 4.14:  Factor Analysis Coefficient of the Specific Items within the Split 
Components (Unrotated) 
  Factor analysis coefficient 
  Test 1 Test 2 
 Questions/Items 1 2 3 1 2 
Q1 
Any of the usual work, housework 
or school activities 
0.85 0.21 -0.14 0.84 0.20 
Q2 
Your usual hobbies, recreational or 
sporting activities 
0.78 0.14 -0.03 0.69 0.01 
Q3 Getting in and out of the bath 0.81 0.36 -0.02 0.81 0.31 
Q4 Walking between rooms 0.76 0.45 0.05 0.73 0.39 
Q5 Putting on shoes or socks 0.61 0.25 0.17 0.64 0.40 
Q6 Squatting 0.80 -0.28 -0.09 0.78 -0.32 
Q7 
Lifting an object, like a bag of 
groceries, from the floor 
0.73 0.13 -0.04 0.77 0.22 
Q8 
Performing light activities around 
your  home 
0.75 0.31 -0.07 0.79 0.13 
Q9 
Performing heavy duties around 
your home 
0.81 0.11 -0.06 0.78 0.02 
Q10 Getting in and out of the car 0.81 0.31 -0.02 0.83 0.21 
Q11 Walking for two blocks 0.75 0.00 0.10 0.76 -0.01 
Q12 Walking for a mile 0.75 0.11 -0.04 0.76 0.20 
Q13 
Going up or down 10 stairs (about 
one  flight of stairs) 
0.82 -0.09 -0.17 0.80 -0.13 
Q14 Standing for one  hour 0.83 -0.18 0.08 0.83 -0.08 
Q15 Sitting for one  hour 0.79 0.02 0.06 0.81 0.16 
Q16 Running on even ground 0.78 -0.50 -0.04 0.76 -0.52 
Q17 Running on uneven ground 0.80 -0.45 -0.06 0.78 -0.47 
Q18 
Making sharp turns while running 
fast 
0.82 -0.42 0.09 0.80 -0.44 
Q19 Hopping. 0.84 -0.34 -0.01 0.80 -0.42 
Q20 Rolling over in bed 0.23 -0.03 0.94 0.72 0.23 
 
The factor analysis results extracted for the rotated items divided the LEFS into two 
constructs (regular and strenuous), as shown in Table 4.15 below.  
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Table 4.15:  Psychometric Sub-Constructs of the LEFS (Rotated) 
 Construct 1 (Regular  activities)  Construct 2 (Strenuous activities) 
Q1 
Any of the usual work, housework or 
school activities 
Q6 Squatting 
Q2 
Your usual hobbies, recreational or 
sporting activities 
Q13 
Going up or down 10 stairs (about 
one flight of stairs) 
Q3 Getting in and out of the bath Q14 Standing for one hour 
Q4 Walking between rooms Q16 Running on even ground 
Q5 Putting on shoes or socks Q17 Running on uneven ground 
Q7 
Lifting an object, like a bag of groceries, 
from the floor 
Q18 Making sharp turns while running fast 
Q8 
Performing light activities around your  
home 
Q19 Hopping 
Q9 
Performing heavy duties around your 
home 
  
Q10 Getting in and out of the car   
Q11 Walking for two blocks   
Q12 Walking a mile   
Q15 Sitting for one hour   
Q20 Rolling over in bed   
 
The results showed that the LEFS items could be classified into regular activities and 
strenuous activities, as shown in Table 4.15. 
 
The internal consistency of the respective components was further tested. This was 
necessary because factor analysis revealed a split in constructs.  
 
Table 4.16:  Internal Consistency of the Rotated Constructs 
 Test 1  Test 2  
Component
s 
N ICC 95%CI p-value N ICC 95%CI p-value 
1 12 0.94 0.92-0.96 0.00 13 0.95 0.93-0.96 0.00 
2 7 0.95 0.93-0.97 0.00 7 0.95 0.92-0.96 0.00 
3 1 - - - - - - - 
 
The ICC showed strong internal consistency which proved to be significant in 
measuring the specific constructs (regular and strenuous activities). Further testing 
was carried out to determine the correlation of each component with the LEFS. This 
was necessary to test which sub-construct contributed to lower extremity function.  
68 
 
Table 4.17:  Spearman’s Rank Order Correlation of the Constructs with the LEFS 
 
4.3. CONCLUSION 
This study measured the test-retest reliability of the LEFS in identifying lower limb 
functional impairment in HIV patients presenting with DSPN. The LEFS showed 
strong test-retest reliability for all activities except for Item 2, namely rolling over in 
bed. The standard error of measurement was 4.88. Factor analysis of the LEFS 
revealed two sub constructs – regular activities and strenuous activities. 
Furthermore, the study showed a high internal consistency and that the duration of 
the HIV infection from date of diagnosis was associated with the severity of the 
DSPN. The mean age of the participants was 38 years and they were mostly 
females. 
 
The highest number of participants had a secondary education and was employed. 
The majority of participants were in Stage 3 of the clinical HIV stages, had been on 
ARVs for 10 to15 years and were taking a combination of ARVs.  
 
The next chapter focuses on a discussion of the implications issuing from the results 
of this study.  
  
  Mean 1  Mean 2  
Rotated 1 0.29 0.00 0.47 0.00 
 2 0.83 0.00 0.73 0.00 
 3 -0.46 <0.001 - - 
69 
 
5. CHAPTER FIVE: DISCUSSION 
 
5.1. INTRODUCTION 
This chapter discusses the results of the data analysis as presented in Chapter Four. 
The aim of the study was to determine the test-retest reliability and internal 
consistency of the LEFS questionnaire as an outcome measure in establishing lower 
limb functioning in patients with HIV-related DSPN.  
 
The results are discussed in line with the following objectives:  
 To establish the test-retest reliability of the LEFS in the measurement of lower 
limb function in HIV-related DSPN in Botswana. 
 To determine the internal consistency of the LEFS for lower limb function in HIV-
related DSPN in Botswana. 
 To describe the demographic and clinical characteristics of HIV patients with 
DSPN in Botswana  
 To determine the construct validity of the LEFS in participants with DSPN in 
Botswana. 
 
5.2. TEST-RETEST RELIABILITY OF THE LEFS IN THE MEASUREMENT OF LOWER 
LIMB FUNCTION IN HIV-RELATED DSPN 
The test–retest reliability of the tool, the LEFS questionnaire, in this sample of HIV-
related DSPN patients was very good. The Spearman’s rank order correlation 
coefficients (rs) were found to range from rs= 0.74 to 0.99. In this study, all questions 
showed strong reliability in patients diagnosed with DSPN, with the exception of one 
item , namely  “rolling over in  bed”, which showed a weak correlation between the 
first and second recordings within the seven-day period.  
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One of the reasons for this anomaly is the possibility that the question around rolling 
over in bed was unclear and in this population may not have been particularly 
relevant - given that most of the participants were ambulant. In spite of this one 
aspect, one can conclude from the results that the LEF tool is reliable for measuring 
lower limb function in patients with DSPN. 
 
As with Tumusiime (2014), our study aimed at determining the test–retest reliability of 
the LEFS in HIV-related DSPN and its internal consistency. The test-retest reliability 
results are comparable to those presented in Tumusiime (2014) study in Rwanda that 
reported a strong test-retest reliability among HIV-infected patients  with  DSPN (rs ≥ 
0.70). The afore-mentioned is but one of the studies that have tested LEFS in an HIV 
group with sensory neuropathy, the results of which can be compared with those of 
this study since the patient group is the same. Lower limb function is important to the 
overall quality of life, and a study by Galantino et al. (2014), showed that HIV-related 
DSPN diminishes the quality of life and the functionality of PLHIV patients on ARVs.   
 
The LEFS has been used in the past to measure function mainly in the lower limb 
and in many different medical scenarios, including  cases where patients have 
undergone anterior cruciate ligament (ACL) reconstruction surgery, and where 
patients have presented with musculoskeletal dysfunction, total knee arthroplasty, 
ankle fractures (Lin, 2009),  diabetes and arthritis (Hoogeboom et al., 2012). Under 
such conditions, the reliability scores were found to range between 0.74 and 0.96.  
 
Yeung et al. (2009) used the test-retest reliability of the LEFS for in-patients in an 
orthopaedic rehabilitation ward with fractures, where the coefficient showed a strong 
reliability of r = 0.88. Binkley et al. (1999) showed that the test-retest reliability of the 
LEFS is extremely sound in musculoskeletal disorders and reported a high r value of 
0.94 (Binkley, 1999).  Similarly, Stratford et al. (2009) found exactly the same level of 
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reliability in a study of patients who had undergone total knee arthroplasty. Alcock et 
al. (2012) revealed that the test-retest reliability of the LEFS in anterior cruciate 
ligament (ACL) reconstruction was high (r = 0.90).  
 
It is encouraging to note that, according to the literature, reliability is attained in all 
conditions, thus making the LEFS a trustworthy tool. For example, in patients who 
had undergone total joint arthroplasty, the r-value reported was r=0.85 (Stratford et 
al., 2009). 
 
In our study, this researcher translated the English version of the LEFS into 
Setswana and back translated it again into English.  In a similar manner, Hou et al. 
(2014)   translated the English version of the LEFS into  Taiwanese and obtained a 
good test-retest reliability result (Hou et al., 2014). Other translated versions of the 
LEFS tool into Italian and Dutch have also shown good reliability (Cacchio et al., 
2010, Negahban et al., 2014).  
 
As noted before, one activity (item) in our study that did not obtain a high correlation 
between Test 1 and Test 2 was rolling over in bed. This is comparable to  the study 
by Tumusiime et al. (2014)  in which he  reported  a weak test–retest reliability level 
for “walking across from one building to another”  (r=0.47)  and for “putting on shoes 
and socks” (r= 0.44).  
The implication of this result is that future research should examine the performance 
of the LEFS in a more heterogeneous HIV population. Part of the reason for this is 
congruent with previous research that has shown that most HIV patients experience 
a phenomenon known as episodic disability (O'Brien et al., 2008). In such a situation, 
patients could experience complete wellness and manage all activities until they 
experience opportunistic infections and periods of illness when they could be 
completely incapacitated (Myezwa et al., 2009). Perhaps further study into the 
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validity of the activities, listed as items in the tables and that affect the responses of a 
population that is ambulant should be undertaken. This was beyond the scope of this 
study and future research should consider this. 
 
In using the LEFS questionnaire in the future, it might be necessary to consider the 
social and environmental context of the activities (items listed in the LEFS) and to 
modify them accordingly. Another reason for considering such adaptations could be 
the differing perceptions that respondents hold in respect of activities, as was noted 
in Rwanda where the population would not normally undertake such activities 
(Tumusiime, 2014). Such modifications to the activities or items in the LEFS 
questionnaire might also be necessary in the case of studies similar to this one.  
 
Another recommendation in the case of this group of Botswana patients infected with 
HIV could be for the concept of rolling over in bed to be reconsidered and reviewed 
for clarity and understanding in the local language.  
 
5.3. INTERNAL CONSISTENCY OF THE LEFS FOR LOWER LIMB FUNCTION IN HIV-
RELATED DSPN 
 
The internal consistency of the LEFS was tested during both Measurement 1 Time 
and Measurement 2 time and found to be high, thus indicating a good internal 
consistency in this study group. This implies that when the LEFS is applied for 
measuring consistency between the respective activities or items within the 
same test, but at different times, the scores are found to be similar and the results 
are therefore consistent.  
 
The results obtained in this study are similar to those reported by (Binkley et al., 
1999a) who,  when using Cronbach’s Alpha index, and testing patients with 
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musculoskeletal disorders,   reported  a result of α=0.96, indicative of a high level of 
internal consistency. Similarly, the LEFS demonstrated a high level of internal 
consistency (α>0.90) in a study were this scale was being applied for its clinometric 
properties to people with ankle fractures (Lin et al., 2009) and to individuals that had 
undergone  ACL reconstruction (ICC=0.90). 
  
Alcock et al. (2012) reported strong internal consistency (ICC =0.90) in their study, 
while the study by Kennedy et al. (2008)  showed  an intra-class correlation on the 
LEFS, indicative of  a strong internal consistency. Similar results were shown by 
Thomas et al. (2012), who conducted a validation study on the Dutch LEFS to 
investigate participants with hip/knee osteoarthritis. With an ICC value of 0.96, the 
Dutch LEFS showed good internal consistency.  
 
In another study, Cacchio et al. (2010) measured the properties of the Italian LEFS 
version in participants who were presenting with lower limb musculoskeletal 
dysfunction. Having calculated Cronbach’s Alpha Index to be α= 0.94 in this case, 
the researchers concluded that the internal consistency of the LEFS was excellent.  
 
With an ICC of 0.92, a good LEFS internal consistency level was shown when Pua et 
al. (2009) undertook a cross-sectional study of community-dwelling adults with hip 
osteoarthritis. These researchers used both the LEFS and the WOMAC-PF scale for 
assessing their sample population. 
 
The calculated ICC for internal consistency of the LEFS in HIV-related DSPN is 
important in that it shows that the stability of the tool is good when it is used on 
separate occasions.  In other words, there is limited variation between the respective 
results (data sets) for two tests of the same items which are conducted at different 
times. The literature reviewed in this study has revealed that the LEFS can be used 
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reliably in researching different disease conditions but that there is a dearth of 
literature to support its use in HIV-related neuropathy.   
 
For the purposes of this study, the LEFS was translated into Setswana and tested for 
its usability and reliability among patients living with HIV and experiencing DSPN. 
Factor analysis was conducted to determine the construct validity of the scale. The 
results for the first data set show that the variables were differentiated into three 
components. When these components were analysed further, they could be 
categorised into separate components, namely difficult activities that are strenuous 
and regular activities that are not so strenuous. The only activity listed in the LEFS 
that did not reflect similar results to the other activities was Item t, namely rolling over 
in bed.  
 
For the second data set, only two components emerged, namely the regular and the 
strenuous activities.  These results show that the LEFS measures the construct of 
lower limb function based on different activities that present different levels of 
challenge to patients at different stages in their illness. 
 
It was interesting and not surprising to note that the analysis for standard error 
measurement revealed that random error was present but that systematic error was 
minimal. The researcher had undertaken the necessary measures in the form of 
training, presenting detailed explanations to patients, translation and back translation, 
and finally ensuring that confidentiality was kept, to ensure that systematic error 
would be kept to  a minimum.   
 
An explanation for the random error that emerged from the statistical analysis of the 
data could be that individual decision-making by the participants cannot be avoided 
when a self-reporting tool such as the LEFS questionnaire is used (Schaeffer, 1996). 
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The demographic and clinical attributes of the participants in this study group proved 
to be interesting in that they revealed, in their collective form, comparable data sets 
and results that could contribute to a better understanding of the epidemiology of 
HIV-related DSPN. 
 
5.4. DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF HIV PATIENTS WITH 
DSPN IN BOTSWANA 
 
In our study, we invited a total of 320 participants for potential inclusion into the 
study, but only 84 were screened as qualifying to go to the next stage of the study. 
Out of the HIV population in the six clinics, 26.3% reported symptoms of sensory 
neuropathy. The prevalence of DSPN within Sub-Saharan Africa that was found in 
other studies was higher than that for our study (Biraguma and Rhoda, 2012, Luma 
et al., 2012, Tumusiime, 2014). In Rwanda, Tumusiime (2014) and Biraguma and 
Rhoda (2012), found a prevalence of 59% and 40% DSPN respectively among  HIV 
patients. 
  
A lower percentage in Botswana is surprising considering that Botswana has been 
reported to have one of the highest HIV prevalence rates in the world and introduced 
the use of ART quite early on in the pandemic (Bennell et al., 1998). With our study, 
Botswana was found to have  a higher number of females with DSPN and this is  
comparable to other sub-Saharan African studies (Biraguma and Rhoda, 2012, 
Tumusiime, 2014). The larger  number of females is  not surprising as generally, the 
prevalence of HIV is higher among females than males in Sub-Saharan Africa (Glynn 
et al., 2001, Ansari et al., 2002). A recent  study by Keetile (2014) reported that a 
third of the females in Botswana are living with HIV whereas  the men living with HIV 
amount to  a quarter of the males population of Botswana.. 
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The age group, 31-40 years, was found to be the one most seriously affected by HIV 
since 32.1% of the participants in the sample population of our study were HIV-
infected.  It was followed by the age group 41-51 years or more.  Similar patterns 
relating to age distribution have been reported in other studies. For example, in a 
study conducted on HIV-related DSPN in Tanzania, the population had a mean age 
of 37 years (Mullin et al., 2011). Furthermore, a study conducted in Gabon which 
investigated the frequency of DSPN in people living with HIV also established that 
the participants’ ages ranged from 17-74 years, with a mean age of 42.1 ± 11 years.  
However, unlike the results of our study, the majority were males (Philomène et al., 
2015).  
 
Even in a better-resourced population in the USA, the reported mean age for HIV-
infected patients was found to be similar to a study by Anziska et al. (2012) on HIV 
DSPN where a mean age of 35 years was reported and which was mainly applicable 
to the female gender.  
 
Another demographic variable that seems consistent in most studies and that 
applies to HIV patients is that of marital status. Many of the patients were single and 
this result was supported by studies on HIV conducted in South Africa (Shisana et 
al., 2009).   In our study, the participants’ level of education was predominantly found 
to be in primary and secondary education and less in tertiary education. The 
distribution of people infected with HIV in South Africa is not  limited to those with no 
or lower education and spans across all levels of education (Myezwa et al., 2009, 
Hanass-Hancock et al., 2016). Most studies on HIV and disability-related studies 
also reported fewer people with tertiary and more with secondary and primary 
education.  In fact, the distribution of participants is often commensurate with the 
country’s educational status.  
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According to a study of HIV in Rwanda (Biraguma and Rhoda, 2012), socio-
economic and educational factors were reported to be a risk factor for the 
development of HIV-related DSPN in this country. Low socio-economic status and 
poor education were reported to predispose women to a higher risk of being infected 
with HIV (Gregson et al., 2005, Shisana et al., 2009, Amuri et al., 2011). 
 
A study of HIV in Gabon showed that 33.5% of the participants were unemployed. 
This figure is higher than the figure (23.8%) for the unemployed HIV-infected 
participants in our study. The majority (63.1%) of the participants in our study had 
reached the secondary educational level. This percentage is higher than the 51.9% 
reported in the Gabon study (Philomène et al., 2015). 
 
The majority of patients in our cohort had lived with HIV for more than 10 years 
(54.7%) from the time of diagnosis and had also been on ART. Philomène et al. 
(2015) considered the stage of the disease and its treatment with medication to be 
very significant in terms of the severity of the presentation of HIV.  
 
In our study, the severity of DSPN was worse within the sample population for 
patients who had lived with the virus for a minimum of 10 years after they had been 
diagnosed with HIV. Thus, a possible explanation that could be offered is that, 
logically, the longer one has lived with the HIV and has been treated with ARV 
drugs, the more likely the damage to the nerve tissue.  
 
Several factors or mechanisms are listed below to explain this: 
a) The direct effect of HIV on nerve tissue (Merrill and Chen, 1991).  
b) The effect of ARV medication. The overall treatment for HIV consists of a number 
of treatments where a number of ARV drugs are administered. Such a regimen 
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increases the risk of mitochondrial toxicity and eventually damages the nervous 
tissue, thus leading to peripheral neuropathy (Smyth et al., 2007).  
c) The aging process being compounded by HIV It was interesting to note that a 
high percentage (73.8%) of DSPN was recorded in the participants taking a 
combination of two to three drugs (O'Brien et al., 2008). This confirms the 
negative effect of ARV medication through its known side effects.  
 
Interestingly, the duration of anti-retroviral therapies and the CD4 cell count were not 
found to be associated with DSPN in Tumusiime (2014). This is contrary to results 
from the Luma et al. (2012) which was conducted to determine adverse drug 
reactions experienced by HIV patients on ARVs. Luma et al. (2012) reported that 
21.2% of all the adverse drug reactions experienced through the administration of 
ARVs were peripheral neuropathy cases.  
 
In our study, all of the HIV patients with DSPN in the sample were in their third and 
fourth clinical stage of the disease, and a large proportion is likely to have been on 
ART for at least six years. The results of our study and those of the study by Luma et 
al. (2012) support the hypothesis that peripheral neuropathy is a prevalent adverse 
reaction to the long-term use of ART .  
 
A common symptom of DSPN is pain and numbness. In our study, pain was the only 
clinical symptom that was measured to assess the severity of the DSPN and on the 
basis of the Visual Analogue Scale. 53.6% of the participants showed moderate 
severity in terms of the pain they were experiencing.  
 
In a  study conducted between 1993 and 2001 in Australia, pain (using the VAS for 
measurement) was found in 56% of the sample population, while 40% and 20% of 
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the participants respectively reported experiencing  numbness and a vibratory 
sensation (Smyth et al., 2007). 
 
A limitation of our study was the omission of numbness and vibratory sensation as 
symptoms justifying measurement. We regarded them as separate from the BPNS 
and recommend that they should be included in future studies of this kind. However, 
in defence of this omission, we wish to state that the purpose of our study was not to 
primarily diagnose DSPN, but to test the reliability and consistency of the 
questionnaire (tool) among the participants, namely Setswana- and English-speaking 
patients, once it had been translated into Setswana. 
 
However it is important to note that one of the clinical findings of our study was that 
the severity of DSPN was found to be moderate in 53.6% of this cohort of patients, 
the results showed an inverse relationship between LEFS measures and the severity 
of the DSPN. This is not surprising since the functional status of a patient, as 
measured on the LEFS, is affected by the severity of the DSPN. The more severe the 
DSPN, the less functional the patient participating in our study would be (Ellis et al., 
2008).  
 
When the associations between the respective socio-demographic attributes and the 
severity of the DSPN were tested, the duration of the HIV infection from the time of 
having been diagnosed was the only factor that showed a significant association with 
the severity of the sensory neuropathy. Again this result was not unexpected 
because of the very nature of the pathological processes presenting in the HIV-ART 
interaction (White et al., 2004). 
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5.5. CONCLUSION  
As the study has shown, the Intra-class correlation (ICC) of the LEFS in HIV-related 
DSPN patients in Botswana confirmed strong test-retest reliability in respect of the 
LEFS questionnaire and the level of performance in the respective activities. The 
results of this study also show that the LEFS tool has good internal consistency and 
is appropriate for monitoring the functionality of the lower limbs in patients with HIV-
related DSPN in Botswana. Since the important task of identifying functional 
limitation in the lower limbs in HIV-related DSPN is an important aspect of 
rehabilitation, it is hoped that the results of this research will have contributed to the 
body of knowledge. Effective tools for facilitating more accurate and easier diagnoses 
would also assist the clinicians in their holistic management of the HIV disease.  
 
The influence of the socio-demographic attributes of gender, age, marital status, level 
of education and occupation on HIV-related DSPN in respect of our study group 
proved to be consistent with the findings of other studies, with the exception of 
gender, where some studies showed a larger proportion of males than females 
suffering from HIV DSPN.  
 
Clinical factors such as the duration of the HIV infection in each of the participants in 
our study from the time of diagnosis, the duration of the administration of the ARTs to 
each of the participants in our study, and the clinical stage into which each of the 
HIV-infected patients could be placed, were analysed to investigate their association 
with DSPN. The most significant clinical factor that was found when testing for the 
association between demographic data and DSPN was found to be the duration of 
the HIV infection in the patient from the time at which it was first diagnosed. 
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The results of this study contribute to a better understanding of HIV-related DSPN 
and the performance of the Lower Extremity Function Scale in terms of test-retest 
reliability, internal consistency, construct validity variance, and the level of 
measurement error. The LEFS can be used with reliability to assess functional 
activity among people living with HIV and DSPN.  
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CHAPTER SIX: CONCLUSION 
 
The LEFS has been used widely in many studies for assessing the effectiveness of a tool 
that is both efficient and fairly quick to use, and able to facilitate comparisons with other 
conditions in the clinical setting. The literature also shows that the LEFS is reliable when 
used in different settings, and that DSPN is common among HIV patients who have been on 
ARV medication for a long time. 
 
The main aim of this study was to establish the test-retest reliability of the Lower Limb 
Functional Scale in HIV-related Distal Sensory Peripheral Neuropathy for patients on anti-
retroviral treatment. On the basis of high correlation coefficients calculated in the respective 
Spearman’s statistical tests on the relevant data, high values, pointing to high levels of test–
retest reliability, were found using this tool when it was administered at two points in  time 7-
10 days apart  among people living with HIV and on ART and experiencing Distal Sensory 
Peripheral Neuropathy. All the activities (items listed in Table 4.8) had strong correlations 
except the functional activity of rolling over in bed, which had a weak correlation.  
 
It is recommended that further studies be conducted in different settings and reflecting 
greater heterogeneity among patients to test the reliability and validity of the tool in 
investigating HIV patients’ perceptions in respect of their performance levels (activities listed 
as items in Table 4.8). These would be useful to ensure that the weak correlation mentioned 
above was not just an outlier and occurring quite by chance. One of the reasons for 
suggesting additional investigations into this matter is that episodic disability is often 
experienced in HIV patients and therefore results in variations in their functional levels.  
 
The Intraclass correlation (ICC) statistics were used to measure the internal consistency of 
the tool in the two measurements which were taken a week apart. Internal consistency was 
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also maintained in the translated version of the LEFS that was used in this study. Therefore, 
the use of the LEFS in different clinical settings in the country of Botswana should be 
possible since good test-retest reliability and internal consistency respectively were 
demonstrated. Furthermore, no major difficulties were experienced in using the LEFS in this 
study.   
 
Construct validity was assessed using factor analysis with Varimax rotation and the un-
rotated model to test whether the specific sub-constructs within the tool contribute to 
the  overall construct of lower limb function. The constructs in the first permutation using the 
rotated model were divided into two components which we categorised as regular activities 
and more strenuous activities. In the un-rotated model, the constructs remained in one 
category. The constructs that contributed to the two components were further tested for 
internal consistency and showed that they do in fact contribute to the components of regular 
and strenuous activity.  
 
Therefore the construct validity of the LEFS used in this Botswana population sample is 
intact.  An interesting observation is that the participants under study were presenting with 
mild to moderate levels of DSPN, and this may account for the split in the sub-constructs. 
Further analysis would be required again in a more heterogeneous population and additional 
less-strenuous activities included for groups with more severe lower extremity functioning 
levels. 
 
Testing for measurement error revealed that random error was present.  This could 
be associated with independent decision-making by individual patients since the LEFS is a 
self-reporting tool.  
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The demographic data showed that the majority of participants were female and living alone, 
thus reflecting a similar gender distribution to those featured in studies conducted in Africa 
and abroad.  
6.1. LIMITATIONS OF THE STUDY 
There was significant resistance from both doctors and patients in private clinics to 
their participation in this study.  On investigation, it became evident that both health-
care staff and patients feared being stigmatised in the event of their information being 
published. This may have skewed the number of patients who agreed to participate 
from the private clinics. This was in spite of the researcher’s assurance that their 
responses to the questionnaire would be treated confidentially through a method of 
encoding the data-collecting tools.  
Government medical facilities were more forthcoming and cooperative but the 
participants admitted to the Infectious Disease Centre as referrals from other remote 
centres, participated initially only.  Their second participation fell by the way owing to 
the problems they experienced in terms of distance and affordability. As such, these 
patients were not considered in the study. In some cases, doctors were too busy to 
assist, thus making recruitment very difficult and slow. 
 
One of the main limitations of our study was the fact that it involved a sample of 
convenience. We could not include patients from the rural areas who had limited 
access to the medical facilities and thus obtain a rural set-up of activities relating to 
functional limitations of patients with HIV-related Distal Sensory Neuropathy.  
 
6.2. FURTHER RECOMMENDATIONS EMANATING FROM THIS STUDY 
This study consisted of a sample of HIV patients suffering from DSPN in an urban 
setting.  As such, a similar study investigating a purely rural population sample of 
participants suffering from HIV-related DSPN might be useful to ensure its reliability 
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across all population groups. Furthermore, there is a need to increase the size of the 
population sample, which could probably be more representative of the larger 
population visiting the available medical facilities in Botswana. 
 
There is a need to do extensive research concerning the construct and concordant 
validity in order to test these aspects against other tools such as the LEFI, the Health 
Status Questionnaire (SF-36), the Health-related Quality of Life (HRQOL) 
Questionnaire and the WOMAC-PF Questionnaire. This will facilitate a wide 
comparison of the functional testing of such individuals suffering from HIV-related 
DSPN and enable them to be monitored in areas where there are no specialists or 
doctors. The rural areas are where we find nurses and other specialised health 
workers conducting health services normally undertaken by better qualified 
professionals such as medical doctors, etc. As such, these self-reporting tools can 
be validated and used to good effect. The reason is that although measures of 
functionality are determined through self-reporting tools such as questionnaires, the 
afore-mentioned are considered valid and can be used to measure functionality 
across different populations with HIV.  
 
This study has established the good test-retest reliability of the LEFS in a population 
of participants with HIV/ART-related DSPN. This study also showed that the LEFS 
has good internal consistency as a tool for investigating a sample population of 
patients with HIV and DSPN. Furthermore, It also has good construct validity but 
revealed the need to distinguish between strenuous and less strenuous activities 
among patients with HIV-related DSPN in Botswana.    
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APPENDIX 1: LOWER EXTREMITY 
FUNCTIONAL SCALE (LEFS) 
 
We are interested in knowing whether you are having any difficulty at all with the activities 
listed below on account of your lower limb problem for which you are currently seeking 
attention. Please provide an answer for each activity.  
Activities  
Today, do you or would you 
have any difficulty at all with 
the following :  
Extreme difficulty 
or unable to 
perform activity  
Consider
able  
difficulty  
Moderate 
difficulty  
Limited 
difficulty  
No 
difficult
y  
1. Any of your usual work, 
housework or school 
activities  
0  1  2  3  4  
2. Your usual hobbies, 
recreational or sporting 
activities  
0  1  2  3  4  
3. Getting into or out of the 
bath  
0  1  2  3  4  
4. Walking between rooms  0  1  2  3  4  
5. Putting on your shoes or 
socks  
0  1  2  3  4  
6. Squatting  0  1  2  3  4  
7. Lifting an object, like a 
bag of groceries, from the 
floor  
0  1  2  3  4  
8. Performing light activities 
around your home  
0  1  2  3  4  
9. Performing heavy 
activities around your home  
0  1  2  3  4  
10. Getting into or out of a 
car  
0  1  2  3  4  
11. Walking for two  blocks  0  1  2  3  4  
12. Walking for a mile  0  1  2  3  4  
13. Going up or down 10 
stairs (about one  flight of 
stairs)  
0  1  2  3  4  
14. Standing for one  hour  0  1  2  3  4  
15. Sitting for one hour  0  1  2  3  4  
16. Running on even 
ground  
0  1  2  3  4  
17. Running on uneven 
ground  
0  1  2  3  4  
18. Making sharp turns 
while running fast  
0  1  2  3  4  
19. Hopping  0  1  2  3  4  
20. Rolling over in bed  0  1  2  3  4  
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SETSWANA VERSION OF THE LOWER LIMB FUNCTIONAL SCALE 
DITAELO 
Re nale kgatlhego ya go itse gore a o nale bothata le go dira ditiri tse di mo mokwalong o o fa tlase 
mo go bakwang ke botsogo jwa maoto a gago.Tsweetswee araba potso nngwe le nngwe e fa tlase 
Gompieno a o nale kgotsa o 
tlaa nna le bothata go dira 
tse difa tlase 
Bothata jo 
bofeteletseng 
kana go sa 
kgone 
gotlhelele 
Bothata jo bo 
tseneletseng 
thata 
Bothata jo 
bo fagare 
mme 
eseng 
thata 
Bothata 
bo bo 
seng 
kae 
Ga 
gona 
bothata 
1.Sepe sa tiro,lapeng kgotsa 
ko sekolong 
0 1 2 3 4 
2.Sepe se o 
seratng,motshameko kapo 
enele ele ithuthuntsho 
0 1 2 3 4 
3.go tsena le go tswa mo 
bateng ya botlhapelo 
0 1 2 3 4 
4.go tsamaya ka dinao 
magareng ga iphaposo 
0 1 2 3 4 
5.go rwala ditlhako le dikausu 0 1 2 3 4 
6.go kotama 0 1 2 3 4 
7.go kuka sepe hela jaaka 
mophuthelo wa dijo o di tsaya 
fa fatshe 
0 1 2 3 4 
8.go tsaya karolo ka go dira 
ditiro tse di motlhofo tsa mo 
gae 
0 1 2 3 4 
9.go tsaya karolo ka go dira 
ditiro tse di bokete mo gae 
0 1 2 3 4 
10.go tsena le go tswa mo 
koloing 
0 1 2 3 4 
11.go tsamaya sekgele sa 
dikago tse pedi 
0 1 2 3 4 
12.go tsamaya lobaka lo le 
leele(sekgala) 
0 1 2 3 4 
13.go ya godimo le ko tlase o 
pagamela ko ntlong e ko 
godimo(matlhatlhaganyane) 
0 1 2 3 4 
14. go ema oura 0 1 2 3 4 
15. go nna oura 0 1 2 3 4 
16. go tsamaya mo lefatsheng 
le le lekanetseng go sena 
dikhuti 
0 1 2 3 4 
17. go tsamaya mo tseleng e 
nang le dikhuti 
0 1 2 3 4 
18.go sheba ntse o tabogile ka 
boheho 
0 1 2 3 4 
19.go tlolatlola 0 1 2 3 4 
20.go iphetsola mo bolaong 0 1 2 3 4 
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APPENDIX 2: SPEARMAN’S CORRELATION 
COEFFICIENTS FOR THE PILOT FIRST AND 
SECOND DATA COLLECTION TIMES FOR THE 
LEFS 
 
Item Functional activities 
 Spearman 
(rs) 
p-value 
1.  
Any of the usual work, housework or 
school activities 
 
0.80 
<0.001 
2.  
Your usual hobbies, recreational or 
sporting activities 
 
0.68 
<0.001 
3.  Getting in and out of the bath 0.97 <0.001 
4.  Walking between rooms 0.97 <0.001 
5.  Putting on shoes or socks 0.91 <0.001 
6.  Squatting 0.96 <0.001 
7.  
Lifting an object, like a bag of 
groceries, from the floor 
0.71 <0.001 
8.  
Performing light activities around your  
home 
0.89 <0.001 
9.  
Performing heavy duties around your 
home 
0.86 <0.001 
10.  Getting in and out of the car 0.85 <0.001 
11.  Walking for two blocks 0.95 <0.001 
12.  Walking for a mile. 0.96 <0.001 
13.  
Going up or down 10 stairs (about one 
flight of stairs). 
0.86 <0.001 
14.  Standing for one hour. 0.94 <0.001 
15.  Sitting for one hour. 0.99 <0.001 
16.  Running on even ground. 1.00  
17.  Running on uneven ground. 0.95 <0.001 
18.  Making sharp turns while running fast 0.96 <0.001 
19.  Hopping 0.85 <0.001 
20.  Rolling over in bed 0.86 <0.001 
 Total Mean 0.89 <0.001 
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APPENDIX 3: BRIEF PERIPHERAL 
NEUROPATHY SCREEN (ENGLISH AND 
SETSWANA) 
ENGLISH 
Please take a few minutes to answer the following questions about the feeling in your legs 
and feet .Check yes or no based on how you usually feel.  
Thank you. 
1.  Do you ever have legs and /feet that feel numb? 
Yes    No  
2.  Do you ever have any burning pain in your legs and/or feet? 
Yes    No  
3.  Are your feet too sensitive to touch? 
Yes    No  
4.  Do you get muscle cramps in your legs and/or feet? 
Yes    No  
5.  Do you ever have any prickling or tingling feelings in your legs or feet? 
Yes    No  
6.  Does it hurt at night or when the covers the covers touch your skin? 
Yes    No  
7.  When you get into the tub or shower, are you unable able to tell the hot water from 
the cold water? 
Yes    No  
8.  Do you ever have any sharp, stabbing, shooting pain in your feet or legs? 
Yes    No  
9.  Have you experienced an asleep feeling or loss of sensation in your legs or feet? 
Yes    No  
10.  Do you feel weak when you walk? 
Yes    No  
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11.  Are your symptoms worse at night? 
Yes    No  
12. Do your legs and/or feet hurt when you walk? 
Yes    No  
13.  Are you unable to sense your feet when you walk? 
Yes    No  
14.  Is the skin on your feet so dry that it cracks open? 
Yes    No  
15.  Have you ever had electric shock-like pain in your feet or legs? 
Yes    No  
 
 
  
102 
 
SETSWANA. 
Tshekatsheko tsa batsaya karolo mo (Peripheral Neuropathy screen) 
 
Code………………………………..                          Letsatsi……………………………… 
 
Tsaya metsotso o arabe dipotso tse di latelang mabapi le ka fa o ikutlwang ka teng mo 
maotong a gago, tshwaya mo lebokosong le le latelang ka fa o ikutlwang ka teng. 
Ka leboga. 
 
1.  A o atle utlwe o sa ikutlwi mo maotong a gago a le bosisi? 
Ee   Nnya  
2.  A o atle o utlwe o na le maoto a botlhoko jo bo fisang? 
Ee   Nnya  
3.  A maoto a gago a utlwa ka bonako fa o a tshwara kana o gata? 
Ee   Nnya  
4.  A ditsheka tsa gago tsa maoto di tshwarwa ke bogatsu? 
Ee  Nnya  
5.  A maoto a gago a na le go tlhabatlhaba fa o tsamaya? 
Ee   Nnya  
6.  A go botlhoko fa dikobo di kgoma letlalo la gago bosigo? 
Ee   Nnya  
7. A o kgona go utlwa maoto a gago fa o tsamaya? 
Ee  Nnya  
8.  A o na le maoto a botlhoko jo bo bogale? 
Ee   Nnya  
9.   A o kile wa tshabelelwa ke go sa utlwa maoto a gago le fa o le mo borokong? 
Ee   Nnya  
10.  A o nna bokoa fa o tsamaya? 
Ee   Nnya  
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11.  A dikai tse tsa botlhoko di a oketsega bosigo? 
Ee   Nnya  
12.  A go botlhoko fa o tsamaya? 
Ee   Nnya  
13.  O kgona go utlwa maoto a gago? 
Ee   Nnya  
14.  A letlalo la maoto a gago le omeletse mo le phatogang? 
Ee   Nnya  
15.  A o atle o nne le go sisimoga mo go tlang le botlhoko mo maotong a gago? 
Ee   Nnya  
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APPENDIX 4: PHYSICIAN’S CHECKLIST FOR 
PERIPHERAL NEUROPATHIES 
 
Demographic characteristics and General health status of the Patient  
 
1.  Gender : Female               Male  
 
2.  Age  : .......................................years 
 
3.  Highest level of Education:  
a) Tertiary education (University, Institution of higher learning)   
b) Secondary School education (S4-6)         
c) Secondary School education (S1-3)       
d) Primary education           
e) Any other (please specify):        
……………………………………………………………………………………… 
 
4.  Occupation 
a) Public (government) service             
b) Peasant (farmer, or livestock)          
c) Self-employed (business)          
d) Private Organisation (NGO, bank, insurance etc)     
e) Unemployed (do not have a job for the last three months)      
f) Any other (please specify):        
……………………………………………………………………………………… 
 
5.  Marital Status 
a) Single          
b) Married           
c) Divorced           
d) Separated          
e) Widow/widower          
f) Cohabitating (live together with a temporally male/female partner)  
g) Any other (please specify):        
……………………………………………………………………………………… 
 
6.  Place of residence.................................................................... (Write it in here) 
 
7.  When the patient’s HIV was diagnosed:  
a) 1 – 6 months ago         
b) 6 – 12 months ago        
c) 1 – 3 years ago         
d) 4 – 6 years ago         
e) 7 – 9 years ago         
f) 1 – 15 years ago          
g) More than 15 years ago        
 
8.  Clinical HIV staging:  
a) Clinical stage I         
b) Clinical stage II         
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c) Clinical stage III         
d) Clinical stage IV         
 
9. Is the patient on Anti-retroviral treatment?  
Yes    No  
 
10.  If yes, please specify the type (s) of ARVs:  
.......................................................................................................................................
.......................................................................................................................................
.......................................................................................................................................
........................................................................................... 
 
11.  For how long the patient has been on ARVs treatment?  
e) 1 – 6 months         
a) 6 – 12 months         
b) 1 – 3 years         
c) 4 – 6 years         
d) 7 – 9 years         
e) 10 – 15 years         
f) More than 15 years        
 
12.  Please indicate if the patient has the following conditions: (Tick that apply)  
 
a) Diabetes mellitus         
b) Vitamin B deficiency        
c) Cancer           
d) Multiple sclerosis         
e) Spinal cord disorders and cognitive problems     
f) Hypothyroidism         
g) Uraemia          
h) Toxic exposure         
i) Hereditary neuropathy        
j) A history of neoplasm        
k) Any other (please specify):        
……………………………………………………………………………………… 
 
13. Please indicate if the patient presents the following symptoms: (Tick all that 
apply)  
 
a) Pain  : Hand and arms   Feet and Legs  
b) Paraesthesia : Hand and arms   Feet and Legs  
c) Numbness  : Hand and arms   Feet and Legs  
 
14.  If the patient presents any of the above symptoms, when did the symptoms 
start? (If remember/recorded)  
 
a) Before start ARVs  
b) After starting ARVs           
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15.  If after start ARVs, after how long on ARVs did the symptoms commence (if 
remember or recorded)  
 
a) 1 – 6 months         
b) 6 – 12 months         
c) 1 – 3 years         
d) 4 – 6 years         
e) More than 6 years         
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SESTWANA 
 
Dipotso tsa bongaka mabapi le go sekwasekwa ga go tlhola bolwetse jwa (Peripheral 
Neuropathies) jo bo amanang le mogare le (ART) (Ka thuso ya tsa booki ba ba berekelang 
ko kokelong ya (ART) 
 
Seemo sa molwetse go tswa mo go tsa botsogo le gore o dirang mo botshelong 
Bong:                   Mme                             Rre    
Dingwaga…………………………………………………  
 
3. Dithuto tsa maemo a kwa godimo 
a) Dithuto tsa maemo a kwagodimo (Mmadikolo)    
b) Sekolo se segolwane sa lokwalo lwa (form 4-5)    
c) Sekolo sa lokwalo lwa (form 1-3)      
d) Sekolo se sebotlana sa (primary)      
        
4.  Tiro 
a) Modiredi wa puso        
b) Molemi morui         
c) Go ipereka (o na le kgwebo)                        
d) Go ikemela ka nosi (kompone)       
e) Ga o bereke (a o na le kgwedi tse tharo o sa bereke)   
f) Go na le tse dingwe di nopole fa di le teng    
                   
5.  Sesupo sa gore a o tserwe/ga wa tsewa 
a) Ga wa nyalwa         
b) O nyetswe         
c) Le tlhalane le mokapelo        
d) Kgaogane le mokapelo       
e) Motlholagadi         
f) Go nna le moratiwa wa gago le sa nyalana     
g) Nopola tse dingwe fa di le teng       
 
6.  Lefelo la bodulo (Kwala mo teng) 
 
7. Molwetse o ne a itse seemo sa gagwe sa mogare go tswa leng fa a sena go 
tlhatlhobiwa 
 
a) Kgwedi ya ntlha go ya go tse di borataro     
b) Kgwedi tse borataro- go ya go tse di lesome le bobedi    
c) Ngwaga wa ntlha-go ya ngwageng tse tharo     
d) Ngwaga tse nne –go ya ngwageng tse di borataro    
e) Ngwaga tse supa-go ya ngwageng tse di bofera bongwe   
f) Ngwaga tse di lesome-go ya ngwageng tse di lesome le botlhano  
g) Ngwaga tse di lesome le botlhano le go feta     
   
  
8.  Kalafi ya mogare go tsamaya kafa e thulagantsweng ka teng ka tatelano 
a) Thulaganyo (stage 1) ya ntlha        
b) Thulaganyo ya bobed        
c) Thulaganyo ya boraro         
d) Thulaganyo ya bone         
 
9.    A molwetse o tsaya diritibatse tsa mogare? 
  1. Ee     2.Nnya  
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10.  Fa e le Ee rurifatsa ka go nopola mofuta wa diritibatsi tsa mogare (ARVs) tse o di 
tsayang 
…………………………………………………………………………………………………
…………………………………………………………………………………………………
………………………………………………………………………… 
 
11.  Ke lobaka le lekae molwetse a tsaya kalafi ya diritibatsi tsa mogare? 
a) Kgwedi ya ntlha go ya go tse borataro       
b) Kgwedi tse borataro -go ya go tse di lesome le bobedi     
c) Ngwaga wa ntlha –go ya dingwageng tse tharo     
d) Ngwaga tse nne –go ya dingwageng tse di borataro    
e) Ngwaga tse supa-go ya dingwageng tse di bofera bongwe   
f) Ngwaga tse di lesome-go ya dingwageng tse di lesome le botlhano  
g) Ngwaga tse di lesome le botlhano le go feta     
 
12. Kopa o supe fa molwetse a na le diemo tsa malwetse a latelang ka go tshwaya mo 
lebokosong: 
 
a) Bolwetse jwa sukiri        
b) Thaelo ya dikotla ya (vit B)        
c) Kankiri          
d) Multiple Sclerosis         
e) Malwetse /makoa a monyetsane le go tlhaloganya le go itse    
f) (Hypothyroidism)         
g) (Uraemia)           
h) Go tsenwa ke tšhefi        
i) Bolwetse jwa (neuropathy) jo bo neelwanang ka losika    
j) Ditso tsa (neoplasm)        
k) A mangwe fa a le teng a nopole………………………………… 
 
13.  Kopa o supe fa molwetse a supa dikai tsa malwetse a latelang ka go tshwaya mo 
lebokosong: 
 
a) Botlhoko  : Mo matsogong   Mo maotong  
b) (Paraesthesia) : Mo matsogong   Mo maotong  
c) Bosisi  : Mo matsogong   Mo maotong  
 
14.  Fa e le gore molwetse o supa dikai tse di fa godimo, di simolotse leng dikai tseo? (Fa 
o gakologelwa) 
 
a) Fa o ese o simolole diritibatsi tsa mogare (ARVs)     
b) Fa o simolola diritibatsi tsa mogare (ARVs)       
 
15.  Fa o sena go simolola diritibatsi, dikai tsa bolwetse ga o bona di simolotse mo 
lobakeng lo lo kafe?(fa o gakologelwa supa ka go tshwaya mo lebokosong) 
 
a) Kgwedi ya ntlha go ya borataro        
b) Kgwedi tse borataro- go ya ko go tse di lesome le bobedi    
c) Ngwaga wa ntlha –go ya go tse tharo       
d) Ngwaga tse nne-go ya go tse di borataro       
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APPENDIX 5: ACTG BRIEF PERIPHERAL 
NEUROPATHY SCREENING TOOL (ENGLISH 
AND SESTWANA) 
 
ENGLISH VERSION 
INSTRUCTIONS FOR RECORDING SUBJECTIVE ELICITED SYMPTOMS 
 
Ask the subject to rate the severity of each symptom listed in questions 1 on a scale of 01 
(mild) to 10(most severe) for right and left feet and legs. Enter the score for each symptom in 
symptom in the columns marked R (right lower limb) and L (left lower limb).If a symptom has 
been present in the past, but not since the last visit, enter 00-Currently Absent. If the system 
never been present, enter “11-Always Been Normal” 
 
Always been 
Normal 
Currently absent Mild..........................................severe 
11 00 01 02 03 04 05 06 07 08 09 
 
1. Symptoms 
R L 
a) Pain, aching, or burning in feet, legs         
b)  “Pins and needles” in feet, legs         
c) Numbness (lack of feeling) in feet, legs        
 
INSTRUCTIONS FOR GRADING SUBJECTIVE ELICITED SYMTOMPS 
 
Use the single highest severity score from question 1.above to obtain a subjective sensory 
neuropathy score. If all severity scores are “00” or “11”, the subjective sensory neuropathy 
score will equal “0” 
 
Presence/Severity Score of 
01-03 = Grade of 1 
04-06 = Grade of 2 
07-10 = Grade of 3 
11 or 00 Grade of 0 
R L 
Subjective Sensory neuropathy grade         
Location of symptoms       
                                        
Use Score Of: 
0 = None 
1 = Feet only 
2 = Extends to ankles 
3 = Extends above ankle but not to knee 
4 = Extends to knees 
5 = Extends above knees 
R L 
a) Pain, aching, or burning in feet, legs        
b) ”Pins “and needles” in feet, legs         
c) “Numbness (lack of feeling) in feet, legs       
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INSTRUCTIONS FOR EVALUATING PERCEPTION OF VIBRATION  
 
Compress the ends of a 128 Hz tuning fork just hard enough that the sides touch. Place the 
vibrating tuning fork on a bony prominence on the subject’s wrist or hand to be sure that they 
can recognize the vibration or “buzzing” quality of the tuning fork. Again, compress the ends 
of the tuning fork just hard enough so that the sides touch. Immediately place the vibrating 
tuning fork gently but firmly on the top of the distal interphalangeal (DIP) joint of one great 
toe and begin counting the seconds. Instruct the subject to tell you when the “buzzing” stops. 
Repeat for the other great toe. 
 
Vibration Perception    
R L 
Great toe DIP joint perception of vibration in seconds      
(a) Vibration perception score  
0 = felt > 10 seconds           
1 = felt 6-10 seconds           
2 = felt < 5 seconds           
3 = not felt            
8 = unable/did not evaluate          
 
INSTRUCTIONS FOR EVALUATING DEEP TENDON REFLEXES  
With the subject seated, the examiner uses one hand to press upward on the ball of the foot, 
dorsiflexing the subject’s ankle to 90 degrees. Using a reflex hammer, the examiner then 
strikes the Achilles tendon. The tendon reflex is felt by the examiner’s hand as a plantar 
flexion of the foot, appearing after a slight delay from the time the Achilles tendon was 
struck. Use reinforcement by having the subject clenches his/her fist before classifying the 
reflex as absent. 
 
Ankle reflexes  
0 = absent  
1 = Hypoactive  
2 = Normal deep tendon reflexes  
3 = Hyperactive  
4 = Clonus  
8 = unable/did not assess 
R L 
Ankle reflexes             
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SESTWANA: ACTG (Brief Peripheral Neuropathy Screening Tool) 
Ditaelo tsa go supa kgatiso ka dikai tsa botlhoko jwa bolwetse mo maotong le mo matsogo: 
 
Kopa kana botsa ka seemo sa bogale jwa dikai tse di boditsweng mo karolong ya ntlha mo 
sekaleng sa (01 botlhoko jo bo fagare)mo leotong la moja le la ko molemeng.Tsenya 
letshwao mo temaneng e tshwailweng (R) le (L).Fa dikai tsa botlhoko di ne di le teng mo 
bogologolong,mme eseng la bofelo o tla o bona ngaka.Tsenya (00)---mo bošheng fa ne go 
sena botlhoko.Fa ne go sena botlhoko tsenya (11)--go supa gore botlhoko ke jo bo 
tlwaelesegileng ka nako tsotlhe. 
 
Botlhoko jo bo 
tlwaelesegileng 
ka nako tsotlhe 
(normal) 
Go tlhoka botlhoko 
mo 
bošheng(currently) 
absent 
 
Mild_________________________severe 
11 00 01 02 03 04 05 06 07 08 09 10 
 
 
R L 
1. Dikai tsa bolwetse (symptoms)                                                                       
a) Botlhoko, le go fisa ga maoto        
b) Ditlhabi mo maotong         
c) Bosisi mo maotong         
 
DITAELO TSA GO SUPA MATSHWAO A MAIKUTLO LE DIKAI TSA BOTLHOKO JWA 
BOLWETSE JWA MAOTO: 
 
Dirisa letshwao lengwe le le kwa godimo le le supang botlhoko jo bo feteletseng mo 
karolong ya ntlha e ko godimo go tsaya matshwao a maikutlo ka bolwetse jwa 
(neuropathy).Fa tsotlhe di supa matshwao a (00) or 11 go raya gore maikutlo otlhe a 
botlhoko ke lefela (0). 
 
Maduo a le teng a bogale jwa botlhoko 
01-03=letshwao la ntlha 
04-06=letshwao la bobedi 
07-10=letshwao la boraro 
11-00=letshwao la lefela                                
 
R L 
2.  Matshwao a maikutlo a letshwao la (neuropathy)      
Dikai tsa bolwetse fa di leng teng         
 
Dirisa matshwao a latelang: 
0 = Ga gona sepe 
1 = Mo leotong fela 
2 = Thapologela ko lenyenana 
3 = Thapologela godimo ga lenyenana mme eseng ko lengoleng 
4 = Thapologela ko mangoleng 
5 = Thapologela ga godimo ga mangole 
R L 
a) Botlhoko jo bo fisang mo maotong       
b) Setlhabi mo maotong.              
c) Bogatsu/Bosisi mo maotong         
 
DITAELO TSA GO SEKASEKA MAIKUTLO A GO UTLWA GO RURUMELA 
 
112 
 
Pataganya bofelo jwa (128 Hz tuning fork)thata mo go lekaneng mo eleng gore la tshwara 
mo ditlhakoreng.Baya motšhini(tuning fork)e rurumang mo lerapong la go iponatsa mo 
letsogong go tlhomamisa gore le kgona go lemoga go ruruma ga boleng jwa motšhini wa 
(tuning fork).Gape,pataganya bofelelo  jwa (tuning fork)fela thata mo go lekaneng mo go 
tshwarang mo di tlhakoreng.Gone fela foo baya (tuning fork)e rurumelang ka bonolo mme e 
gateleditswe godimo ga “distal interphalangeal (DIP) mo makopanelong a nngwe ya 
monwana o mogolo o bo simolola go bala metsotswana.Go tla nna le kaetso ya gore go 
rurumela ga motšhini go ema leng.Boeletsa monwana o mongwe yo mogolo. 
 
R L 
Maikutlo a go utlwa ga go rurumela 
a) Maikutlo a go rurumela mo monwaneng o motona  
     (DIP) fa bokopanelong ka metsotswana       
b) Matshwao a maikutlo a go rurumela ka metsotswana     
 
Lefela=La metsotswana >Lesome         
Bongwe=Metsotswana-borataro-lesome        
Bobedi=metsotso<b otlhano         
Boraro=Go sa utlwale sepe          
Bofera bobedi=Go sena tshekatsheko        
 
Ditaelo tsa go sekaseka boteng jwa mosifa wa motsamao                                                           
Fa o dutse fatshe,motlhatlhobi o dirisa seatla sele sengwe go tobetsa go ya kwa godimo mo 
bolong ya leoto,(dorgiflexing the subjects ankle)go ya selekanyong sa 90(degrees).O dirisa 
sekokotelo sa(reflex hammer),Go tswa fong motlhatlhobi o itaya mosifa ba go bitsang bare 
(Achilles Tendon).Go tswa fa mosifa o utlwiwa ke motlhatlhobi ka letsogo jaaka(plantar 
flexion)ya leoto,e be go iponatsa morago go sena go diega go sekaenyana go tswa mo 
nakong e go iteilweng ka sekokotelo sa(reflex hammer)mo (Achilles Tendon).Dirisa 
thatafatso o tsentse huparela mo feising pele ga o kgaoganya motsamao jaaka o sena sepe. 
 
Motsamao wa Lenyenana 
0 = ga gona sepe 
1 = Hypoactive 
2 = Boteng jwa mosifa jo bo siameng 
3 = Go le matlhagatlhaga 
4 = Clonus 
8 = Ga ke kgone go sekaseka 
 
R L 
Motsamao wa lenyenana (reflexes)                 
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APPENDIX 6: ETHICAL CLEARANCE 
UNIVERSITY OF THE WITWATERSRAND 
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APPENDIX 7: ETHICAL CLEARANCE: 
PRINCESS MARINA HOSPITAL 
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APPENDIX 8: TURN-IT-IN REPORT 
 
